<!DOCTYPE html>
<html lang="tr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Hematoloji Onkoloji â€” AkÄ±llÄ± Ä°laÃ§lar & LÃ¶semiler</title>
<link href="https://fonts.googleapis.com/css2?family=DM+Mono:ital,wght@0,400;0,500;1,400&family=Fraunces:ital,opsz,wght@0,9..144,300;0,9..144,600;0,9..144,800;1,9..144,300;1,9..144,500&display=swap" rel="stylesheet">
<style>
:root{
  --bg:#080c10;--bg2:#0c1118;--bg3:#111820;
  --card:#0e1520;--border:#192030;--border2:#1e2d40;
  --red:#e85c5c;--red-d:rgba(232,92,92,.11);
  --amber:#e8a24a;--amber-d:rgba(232,162,74,.11);
  --teal:#3dd6c8;--teal-d:rgba(61,214,200,.09);
  --green:#4ecb87;--green-d:rgba(78,203,135,.09);
  --blue:#5a9cf5;--blue-d:rgba(90,156,245,.09);
  --purple:#b07ef5;--purple-d:rgba(176,126,245,.09);
  --pink:#f57eb0;--pink-d:rgba(245,126,176,.09);
  --txt:#c0d0e5;--txt-d:#4e6a85;--txt-m:#7a9ab8;--wh:#e5eef8;
}
*{margin:0;padding:0;box-sizing:border-box}
html{scroll-behavior:smooth}
body{font-family:'Fraunces',Georgia,serif;background:var(--bg);color:var(--txt);min-height:100vh;overflow-x:hidden}
body::before{content:'';position:fixed;inset:0;background:radial-gradient(ellipse 80% 50% at 20% -10%,rgba(61,214,200,.04),transparent),radial-gradient(ellipse 60% 40% at 80% 110%,rgba(90,156,245,.04),transparent);pointer-events:none;z-index:0}
body::after{content:'';position:fixed;inset:0;background-image:url("data:image/svg+xml,%3Csvg viewBox='0 0 200 200' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='n'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.85' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23n)' opacity='0.025'/%3E%3C/svg%3E");pointer-events:none;z-index:999}

/* â”€â”€ LOGIN â”€â”€ */
#loginScreen{position:fixed;inset:0;z-index:200;background:var(--bg);display:flex;align-items:center;justify-content:center;transition:opacity .5s}
.login-wrap{width:min(460px,92vw);text-align:center;position:relative;z-index:1}
.login-badge{display:inline-flex;align-items:center;gap:8px;font-family:'DM Mono',monospace;font-size:10px;letter-spacing:3px;color:var(--teal);border:1px solid rgba(61,214,200,.3);background:var(--teal-d);padding:6px 16px;border-radius:24px;margin-bottom:28px;text-transform:uppercase}
.login-title{font-size:clamp(30px,5vw,48px);font-weight:800;line-height:1.1;color:var(--wh);margin-bottom:8px;letter-spacing:-1.5px}
.login-title em{font-style:italic;color:var(--amber)}
.login-sub{font-size:12px;color:var(--txt-d);margin-bottom:36px;font-family:'DM Mono',monospace;letter-spacing:.8px}
.login-field{background:var(--card);border:1px solid var(--border2);border-radius:12px;padding:15px 20px;font-family:'DM Mono',monospace;font-size:14px;color:var(--wh);width:100%;outline:none;margin-bottom:12px;transition:border-color .2s,box-shadow .2s}
.login-field:focus{border-color:var(--teal);box-shadow:0 0 0 3px rgba(61,214,200,.08)}
.login-field::placeholder{color:var(--txt-d)}
.btn-login{width:100%;background:linear-gradient(135deg,var(--teal),#2bada1);color:#061110;border:none;border-radius:12px;padding:16px;font-family:'Fraunces',serif;font-weight:800;font-size:16px;cursor:pointer;transition:transform .2s,box-shadow .2s;letter-spacing:.2px}
.btn-login:hover{transform:translateY(-2px);box-shadow:0 14px 36px rgba(61,214,200,.28)}
.login-note{font-size:11px;color:var(--txt-d);margin-top:14px;font-family:'DM Mono',monospace}

/* â”€â”€ APP â”€â”€ */
#app{display:none;min-height:100vh;position:relative;z-index:1}
.topbar{position:sticky;top:0;z-index:60;background:rgba(8,12,16,.94);backdrop-filter:blur(16px);border-bottom:1px solid var(--border);padding:0 24px;display:flex;align-items:center;justify-content:space-between;height:54px}
.topbar-brand{font-weight:800;font-size:16px;color:var(--wh);letter-spacing:-.5px;display:flex;align-items:center;gap:8px}
.topbar-brand .dot{width:8px;height:8px;border-radius:50%;background:var(--teal);animation:breathe 3s ease-in-out infinite}
@keyframes breathe{0%,100%{opacity:1;transform:scale(1)}50%{opacity:.5;transform:scale(.8)}}
.topbar-right{display:flex;align-items:center;gap:10px}
.topbar-user{font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d);padding:5px 12px;background:var(--card);border:1px solid var(--border);border-radius:20px}
.tts-btn{background:var(--teal-d);border:1px solid rgba(61,214,200,.3);color:var(--teal);padding:7px 14px;border-radius:20px;font-family:'DM Mono',monospace;font-size:11px;cursor:pointer;transition:all .2s}
.tts-btn.speaking{animation:pulse 1.4s infinite}
@keyframes pulse{0%,100%{box-shadow:0 0 0 0 rgba(61,214,200,.4)}50%{box-shadow:0 0 0 8px rgba(61,214,200,0)}}
.logout-btn{background:none;border:1px solid var(--border2);color:var(--txt-d);padding:7px 12px;border-radius:20px;font-family:'DM Mono',monospace;font-size:10px;cursor:pointer;transition:all .2s}
.logout-btn:hover{border-color:var(--red);color:var(--red)}
.progress-bar{height:2px;background:var(--border)}
.progress-fill{height:100%;background:linear-gradient(90deg,var(--teal),var(--blue),var(--purple));transition:width .7s cubic-bezier(.4,0,.2,1)}
.sec-nav{display:flex;overflow-x:auto;gap:3px;padding:8px 20px;border-bottom:1px solid var(--border);background:rgba(8,12,16,.7);backdrop-filter:blur(8px);scrollbar-width:none}
.sec-nav::-webkit-scrollbar{display:none}
.sec-tab{white-space:nowrap;padding:7px 14px;background:none;border:1px solid transparent;border-radius:8px;font-family:'DM Mono',monospace;font-size:10px;letter-spacing:.6px;color:var(--txt-d);cursor:pointer;transition:all .2s;text-transform:uppercase}
.sec-tab:hover{color:var(--txt);border-color:var(--border2);background:rgba(255,255,255,.02)}
.sec-tab.active{background:var(--teal-d);border-color:rgba(61,214,200,.4);color:var(--teal)}

/* â”€â”€ MAIN â”€â”€ */
.main{max-width:940px;margin:0 auto;padding:44px 24px 88px}
.sec-page{display:none;animation:fadeUp .4s cubic-bezier(.4,0,.2,1)}
.sec-page.active{display:block}
@keyframes fadeUp{from{opacity:0;transform:translateY(16px)}to{opacity:1;transform:translateY(0)}}
.page-tag{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:3px;text-transform:uppercase;color:var(--teal);margin-bottom:12px;display:flex;align-items:center;gap:10px}
.page-tag::after{content:'';flex:1;height:1px;background:linear-gradient(90deg,rgba(61,214,200,.3),transparent)}
.page-h1{font-size:clamp(28px,4.5vw,44px);font-weight:800;color:var(--wh);line-height:1.1;letter-spacing:-1.5px;margin-bottom:10px}
.page-h1 em{font-style:italic;color:var(--amber)}
.page-intro{font-size:15px;color:var(--txt-m);line-height:1.75;max-width:720px;margin-bottom:32px;border-left:2px solid var(--teal);padding-left:16px}
.sec-title{font-size:16px;font-weight:700;color:var(--wh);margin:28px 0 14px;display:flex;align-items:center;gap:10px}
.sec-title::after{content:'';flex:1;height:1px;background:var(--border)}

/* â”€â”€ CARDS â”€â”€ */
.card-row{display:grid;grid-template-columns:repeat(auto-fit,minmax(220px,1fr));gap:12px;margin-bottom:22px}
.card{background:var(--card);border:1px solid var(--border);border-radius:12px;padding:20px;position:relative;overflow:hidden;transition:border-color .25s,transform .18s}
.card:hover{border-color:var(--border2);transform:translateY(-2px)}
.card-top{position:absolute;top:0;left:0;right:0;height:2px;border-radius:2px 2px 0 0}
.card-top.teal{background:linear-gradient(90deg,var(--teal),transparent)}
.card-top.red{background:linear-gradient(90deg,var(--red),transparent)}
.card-top.amber{background:linear-gradient(90deg,var(--amber),transparent)}
.card-top.blue{background:linear-gradient(90deg,var(--blue),transparent)}
.card-top.green{background:linear-gradient(90deg,var(--green),transparent)}
.card-top.purple{background:linear-gradient(90deg,var(--purple),transparent)}
.card-top.pink{background:linear-gradient(90deg,var(--pink),transparent)}
.card-icon{font-size:24px;margin-bottom:10px}
.card-lbl{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:1.8px;color:var(--txt-d);text-transform:uppercase;margin-bottom:6px}
.card-val{font-size:18px;font-weight:700;color:var(--wh);margin-bottom:6px;font-family:'DM Mono',monospace;line-height:1.2}
.card-desc{font-size:12.5px;color:var(--txt-d);line-height:1.6}
sup.ref{font-family:'DM Mono',monospace;font-size:9px;color:var(--teal);cursor:help;vertical-align:super;line-height:0;padding:0 1px;transition:color .2s}
sup.ref:hover{color:var(--amber)}

/* â”€â”€ INFO BOXES â”€â”€ */
.info-box{border-radius:10px;padding:16px 18px;margin-bottom:14px;font-size:13.5px;line-height:1.8;border-left:3px solid}
.info-box.teal{background:var(--teal-d);border-color:var(--teal)}
.info-box.red{background:var(--red-d);border-color:var(--red)}
.info-box.amber{background:var(--amber-d);border-color:var(--amber)}
.info-box.blue{background:var(--blue-d);border-color:var(--blue)}
.info-box.green{background:var(--green-d);border-color:var(--green)}
.info-box.purple{background:var(--purple-d);border-color:var(--purple)}
.info-box.pink{background:var(--pink-d);border-color:var(--pink)}
.info-box strong{color:var(--wh)}
.info-box code{font-family:'DM Mono',monospace;font-size:11px;background:rgba(255,255,255,.08);padding:2px 7px;border-radius:4px;color:var(--teal)}

/* â”€â”€ TABLES â”€â”€ */
.tbl-wrap{background:var(--card);border:1px solid var(--border);border-radius:12px;overflow:hidden;margin-bottom:22px}
.tbl-cap{font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d);padding:12px 16px 0}
.tbl-wrap table{width:100%;border-collapse:collapse}
.tbl-wrap th{background:var(--bg3);font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.5px;text-transform:uppercase;color:var(--txt-d);padding:11px 16px;text-align:left;border-bottom:1px solid var(--border)}
.tbl-wrap td{padding:12px 16px;font-size:12.5px;border-bottom:1px solid rgba(25,32,48,.7);vertical-align:top;line-height:1.6}
.tbl-wrap tr:last-child td{border-bottom:none}
.tbl-wrap tr:hover td{background:rgba(61,214,200,.02)}
.mono{font-family:'DM Mono',monospace;font-size:11.5px;color:var(--teal)}
.badge{display:inline-block;padding:2px 9px;border-radius:20px;font-size:9.5px;font-family:'DM Mono',monospace;white-space:nowrap}
.badge.red{background:var(--red-d);color:var(--red);border:1px solid rgba(232,92,92,.3)}
.badge.teal{background:var(--teal-d);color:var(--teal);border:1px solid rgba(61,214,200,.3)}
.badge.amber{background:var(--amber-d);color:var(--amber);border:1px solid rgba(232,162,74,.3)}
.badge.green{background:var(--green-d);color:var(--green);border:1px solid rgba(78,203,135,.3)}
.badge.blue{background:var(--blue-d);color:var(--blue);border:1px solid rgba(90,156,245,.3)}
.badge.purple{background:var(--purple-d);color:var(--purple);border:1px solid rgba(176,126,245,.3)}
.badge.pink{background:var(--pink-d);color:var(--pink);border:1px solid rgba(245,126,176,.3)}

/* â”€â”€ DRUG CARDS â”€â”€ */
.drug-grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(256px,1fr));gap:12px;margin-bottom:22px}
.drug-card{background:var(--card);border:1px solid var(--border);border-radius:11px;padding:18px;position:relative;overflow:hidden;transition:all .2s}
.drug-card:hover{transform:translateY(-2px);border-color:var(--border2)}
.drug-card::before{content:'';position:absolute;top:0;left:0;right:0;height:2px}
.drug-card.cd20::before{background:var(--blue)}
.drug-card.cd30::before{background:var(--purple)}
.drug-card.cd33::before{background:var(--amber)}
.drug-card.her2::before{background:var(--pink)}
.drug-card.vegf::before{background:var(--teal)}
.drug-card.egfr::before{background:var(--green)}
.drug-card.braf::before{background:var(--red)}
.drug-card.checkpoint::before{background:linear-gradient(90deg,var(--amber),var(--red))}
.drug-card.btk::before{background:var(--purple)}
.drug-card.other::before{background:var(--txt-d)}
.drug-name{font-size:14px;font-weight:700;color:var(--wh);margin-bottom:4px}
.drug-target{font-family:'DM Mono',monospace;font-size:10px;color:var(--teal);margin-bottom:8px;display:flex;align-items:center;gap:6px}
.drug-target span{opacity:.5}â†’
.drug-indication{font-size:12px;color:var(--txt-d);line-height:1.55;margin-bottom:8px}
.drug-note{font-size:11.5px;padding:7px 10px;border-radius:6px;margin-top:8px;border-left:2px solid;line-height:1.55}
.drug-note.warn{background:var(--red-d);border-color:var(--red);color:var(--red)}
.drug-note.tip{background:var(--amber-d);border-color:var(--amber);color:var(--amber)}
.drug-note.info{background:var(--teal-d);border-color:var(--teal);color:var(--teal)}
.drug-note.exam{background:var(--purple-d);border-color:var(--purple);color:var(--purple)}

/* â”€â”€ ACCORDION â”€â”€ */
.accord{display:flex;flex-direction:column;gap:8px;margin-bottom:22px}
.accord-item{background:var(--card);border:1px solid var(--border);border-radius:10px;overflow:hidden}
.accord-head{display:flex;align-items:center;gap:14px;padding:15px 18px;cursor:pointer;transition:background .2s}
.accord-head:hover{background:rgba(255,255,255,.018)}
.accord-item.open .accord-head{border-bottom:1px solid var(--border)}
.accord-num{font-family:'DM Mono',monospace;font-size:11px;color:var(--teal);min-width:20px}
.accord-title{font-size:14px;font-weight:600;color:var(--wh);flex:1;line-height:1.35}
.accord-toggle{font-size:16px;color:var(--txt-d);transition:transform .28s;flex-shrink:0}
.accord-item.open .accord-toggle{transform:rotate(45deg);color:var(--teal)}
.accord-body{font-size:13px;color:var(--txt-m);line-height:1.8;max-height:0;overflow:hidden;transition:max-height .4s ease,padding .3s}
.accord-item.open .accord-body{max-height:1000px;padding:16px 18px}

/* â”€â”€ CASE BOX â”€â”€ */
.case-box{background:var(--bg2);border:1px solid var(--border2);border-radius:12px;padding:22px;margin-bottom:22px;position:relative;overflow:hidden}
.case-box::before{content:'VAKA';position:absolute;top:16px;right:16px;font-family:'DM Mono',monospace;font-size:9px;letter-spacing:3px;color:var(--txt-d);border:1px solid var(--border2);padding:4px 10px;border-radius:20px}
.case-q{font-size:14px;color:var(--wh);line-height:1.7;margin-bottom:14px}
.case-findings{display:flex;flex-wrap:wrap;gap:8px;margin-top:12px}
.case-finding{font-family:'DM Mono',monospace;font-size:11px;padding:5px 12px;border-radius:6px;border:1px solid}

/* â”€â”€ FLOW / ALGORITHM â”€â”€ */
.algo{display:flex;flex-direction:column;gap:2px;margin-bottom:22px}
.algo-row{display:flex;gap:14px}
.algo-conn{width:32px;flex-shrink:0;display:flex;flex-direction:column;align-items:center}
.algo-dot{width:10px;height:10px;border-radius:50%;border:2px solid var(--teal);background:var(--bg);flex-shrink:0;margin-top:5px}
.algo-line{flex:1;width:2px;background:linear-gradient(var(--teal),rgba(61,214,200,.08));min-height:24px}
.algo-row:last-child .algo-line{display:none}
.algo-content{background:var(--card);border:1px solid var(--border);border-radius:9px;padding:14px 16px;flex:1;margin-bottom:6px;transition:border-color .2s}
.algo-content:hover{border-color:rgba(61,214,200,.25)}
.algo-lbl{font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.5px;text-transform:uppercase;color:var(--teal);margin-bottom:5px}
.algo-txt{font-size:13px;color:var(--txt);line-height:1.6}
.algo-note{font-size:11.5px;color:var(--txt-d);margin-top:5px;font-family:'DM Mono',monospace}

/* â”€â”€ PATHWAY VISUAL â”€â”€ */
.pathway{display:flex;align-items:center;flex-wrap:wrap;gap:0;margin-bottom:18px;background:var(--card);border:1px solid var(--border);border-radius:10px;padding:18px;overflow-x:auto}
.pway-node{display:flex;flex-direction:column;align-items:center;min-width:80px;text-align:center}
.pway-icon{width:44px;height:44px;border-radius:50%;display:flex;align-items:center;justify-content:center;font-size:18px;margin-bottom:6px;border:2px solid}
.pway-lbl{font-family:'DM Mono',monospace;font-size:9.5px;color:var(--txt-d);letter-spacing:.8px;text-align:center;line-height:1.3}
.pway-arrow{font-size:20px;color:var(--border2);margin:0 4px;flex-shrink:0;align-self:center;margin-bottom:20px}
.pway-blocked{position:relative}
.pway-blocked::after{content:'ğŸš«';position:absolute;top:-8px;right:-8px;font-size:14px}

/* â”€â”€ REFS â”€â”€ */
.refs-box{background:var(--bg2);border:1px solid var(--border);border-radius:10px;padding:18px 20px;margin-top:28px}
.refs-title{font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:2px;text-transform:uppercase;color:var(--txt-d);margin-bottom:14px;display:flex;align-items:center;gap:10px}
.refs-title::after{content:'';flex:1;height:1px;background:var(--border)}
.ref-list{list-style:none;display:flex;flex-direction:column;gap:7px}
.ref-list li{font-size:11.5px;color:var(--txt-d);line-height:1.55;display:flex;gap:10px;font-family:'DM Mono',monospace}
.ref-list .rn{color:var(--teal);min-width:24px;font-weight:700}

/* â”€â”€ SECTION NAV BUTTONS â”€â”€ */
.sec-nav-btn{display:flex;justify-content:space-between;align-items:center;margin-top:36px;padding-top:22px;border-top:1px solid var(--border);gap:10px}
.btn-prev,.btn-next-sec{display:inline-flex;align-items:center;gap:8px;padding:12px 24px;border-radius:9px;font-family:'Fraunces',serif;font-size:14px;font-weight:700;cursor:pointer;border:none;transition:all .2s}
.btn-next-sec{background:linear-gradient(135deg,var(--teal),#28aba0);color:#06100f}
.btn-next-sec:hover{transform:translateY(-2px);box-shadow:0 10px 28px rgba(61,214,200,.22)}
.btn-prev{background:none;color:var(--txt-m);border:1px solid var(--border2)}
.btn-prev:hover{border-color:var(--teal);color:var(--teal)}

/* â”€â”€ QUIZ â”€â”€ */
.quiz-prog{display:flex;align-items:center;justify-content:space-between;margin-bottom:18px}
.quiz-prog-lbl{font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d)}
.quiz-score{font-family:'DM Mono',monospace;font-size:12px}
.quiz-score .c{color:var(--green)} .quiz-score .w{color:var(--red)}
.quiz-card{background:var(--card);border:1px solid var(--border);border-radius:14px;padding:26px;margin-bottom:14px}
.quiz-q{font-size:16.5px;font-weight:600;color:var(--wh);line-height:1.5;margin-bottom:20px}
.quiz-opts{display:flex;flex-direction:column;gap:9px}
.quiz-opt{display:flex;align-items:flex-start;gap:12px;background:var(--bg3);border:1px solid var(--border);border-radius:9px;padding:13px 16px;cursor:pointer;font-size:13px;color:var(--txt);transition:all .2s;text-align:left}
.quiz-opt:hover:not([disabled]){border-color:rgba(61,214,200,.5);background:rgba(61,214,200,.03)}
.opt-key{font-family:'DM Mono',monospace;font-size:10px;font-weight:700;color:var(--txt-d);min-width:22px;height:22px;border:1px solid var(--border2);border-radius:4px;display:flex;align-items:center;justify-content:center;flex-shrink:0;margin-top:1px;transition:all .2s}
.quiz-opt.correct{border-color:var(--green);background:var(--green-d);color:var(--green)}
.quiz-opt.correct .opt-key{background:var(--green);color:#041808;border-color:var(--green)}
.quiz-opt.wrong{border-color:var(--red);background:var(--red-d);color:var(--red)}
.quiz-opt.wrong .opt-key{background:var(--red);color:#fff;border-color:var(--red)}
.quiz-opt[disabled]{cursor:default}
.quiz-fb{border-radius:9px;padding:14px 16px;font-size:13px;line-height:1.7;display:none;margin-top:12px}
.quiz-fb.show{display:block}
.quiz-fb.ok{background:var(--green-d);border:1px solid rgba(78,203,135,.3);color:#aaffe0}
.quiz-fb.ko{background:var(--red-d);border:1px solid rgba(232,92,92,.3);color:#ffc2c2}
.quiz-actions{display:flex;justify-content:flex-end;margin-top:16px}
.btn-qnext{background:linear-gradient(135deg,var(--teal),#28aba0);color:#06100f;border:none;border-radius:9px;padding:11px 24px;font-family:'Fraunces',serif;font-weight:700;font-size:14px;cursor:pointer;transition:transform .2s,box-shadow .2s}
.btn-qnext:hover:not([disabled]){transform:translateY(-2px);box-shadow:0 10px 24px rgba(61,214,200,.22)}
.btn-qnext[disabled]{opacity:.35;cursor:not-allowed}

/* â”€â”€ RESULT â”€â”€ */
.result-wrap{text-align:center;padding:44px 20px}
.ring-wrap{position:relative;width:160px;height:160px;margin:0 auto 24px}
.ring-wrap svg{transform:rotate(-90deg)}
.ring-bg{fill:none;stroke:var(--border);stroke-width:9}
.ring-fill{fill:none;stroke:var(--teal);stroke-width:9;stroke-linecap:round;stroke-dasharray:452;stroke-dashoffset:452;transition:stroke-dashoffset 1.6s cubic-bezier(.4,0,.2,1)}
.ring-inner{position:absolute;inset:0;display:flex;flex-direction:column;align-items:center;justify-content:center}
.ring-pct{font-family:'DM Mono',monospace;font-size:32px;font-weight:700;color:var(--teal);line-height:1}
.ring-sub{font-size:9px;color:var(--txt-d);font-family:'DM Mono',monospace;letter-spacing:1px;margin-top:4px}
.result-title{font-size:26px;font-weight:800;color:var(--wh);margin-bottom:8px}
.result-desc{font-size:13.5px;color:var(--txt-d);max-width:440px;margin:0 auto 24px;line-height:1.7}
.result-stats{display:flex;gap:10px;justify-content:center;flex-wrap:wrap;margin-bottom:28px}
.stat-box{background:var(--card);border:1px solid var(--border);border-radius:10px;padding:13px 20px;font-family:'DM Mono',monospace;text-align:center;min-width:80px}
.stat-val{font-size:24px;font-weight:700;display:block;margin-bottom:3px}
.stat-lbl{font-size:9.5px;color:var(--txt-d);letter-spacing:1px}
.result-btns{display:flex;gap:10px;justify-content:center;flex-wrap:wrap}
.btn-retry{background:var(--teal-d);color:var(--teal);border:1px solid rgba(61,214,200,.3);border-radius:9px;padding:12px 24px;font-family:'Fraunces',serif;font-weight:700;font-size:14px;cursor:pointer;transition:all .2s}
.btn-retry:hover{background:rgba(61,214,200,.18)}
.btn-review-all{background:none;color:var(--txt-m);border:1px solid var(--border2);border-radius:9px;padding:12px 24px;font-family:'Fraunces',serif;font-weight:600;font-size:14px;cursor:pointer;transition:all .2s}
.btn-review-all:hover{border-color:var(--teal);color:var(--teal)}

/* â”€â”€ HISTORY â”€â”€ */
.hist-list{display:flex;flex-direction:column;gap:9px}
.hist-item{background:var(--card);border:1px solid var(--border);border-radius:10px;padding:15px 18px;display:flex;align-items:center;gap:14px}
.hist-rank{font-family:'DM Mono',monospace;font-size:10px;color:var(--txt-d);min-width:20px}
.hist-score{font-family:'DM Mono',monospace;font-size:20px;font-weight:700;min-width:54px}
.hist-meta{flex:1}
.hist-date{font-family:'DM Mono',monospace;font-size:10.5px;color:var(--txt-d)}
.hist-correct{font-size:12.5px;color:var(--txt-m);margin-top:2px}
.empty-hist{text-align:center;padding:48px;color:var(--txt-d);font-family:'DM Mono',monospace;font-size:13px}

@media(max-width:600px){
  .card-row{grid-template-columns:1fr}
  .drug-grid{grid-template-columns:1fr}
  .topbar-user{display:none}
  .sec-nav-btn{flex-direction:column}
  .btn-prev,.btn-next-sec{width:100%;justify-content:center}
}
</style>
</head>
<body>

<!-- â•â•â• LOGIN â•â•â• -->
<div id="loginScreen">
  <div class="login-wrap">
    <div class="login-badge">ğŸ©¸ Hematoloji & Onkoloji</div>
    <h1 class="login-title">AkÄ±llÄ± Ä°laÃ§lar &<br><em>LÃ¶semiler</em></h1>
    <p class="login-sub">NCCN 2025 Â· ASCO KÄ±lavuzlarÄ± Â· GÃ¼ncel LiteratÃ¼r</p>
    <input class="login-field" id="loginName" type="text" placeholder="AdÄ±nÄ±zÄ± girin (Ã¶rn. Dr. Zeynep)" maxlength="40">
    <button class="btn-login" id="loginBtn">ModÃ¼le BaÅŸla â†’</button>
    <p class="login-note">Verileriniz yalnÄ±zca bu tarayÄ±cÄ±da saklanÄ±r.</p>
  </div>
</div>

<!-- â•â•â• APP â•â•â• -->
<div id="app">
<div class="topbar">
  <div class="topbar-brand"><div class="dot"></div>Hema<span style="color:var(--teal)">Onko</span></div>
  <div class="topbar-right">
    <span class="topbar-user" id="topbarUser"></span>
    <button class="tts-btn" id="ttsBtn">ğŸ”Š Sesli Oku</button>
    <button class="logout-btn" id="logoutBtn">Ã‡Ä±kÄ±ÅŸ</button>
  </div>
</div>
<div class="progress-bar"><div class="progress-fill" id="topProgress" style="width:0%"></div></div>
<nav class="sec-nav" id="secNav">
  <button class="sec-tab active" data-sec="s1" data-prog="0">01 Â· TÃ¼ylÃ¼ HÃ¼cre</button>
  <button class="sec-tab" data-sec="s2" data-prog="16">02 Â· KLL & Akut</button>
  <button class="sec-tab" data-sec="s3" data-prog="32">03 Â· CD20/30/33</button>
  <button class="sec-tab" data-sec="s4" data-prog="48">04 Â· HER2Â·VEGFÂ·EGFR</button>
  <button class="sec-tab" data-sec="s5" data-prog="64">05 Â· Checkpoint</button>
  <button class="sec-tab" data-sec="s6" data-prog="80">06 Â· BRAF & Ã–zel</button>
  <button class="sec-tab" data-sec="sq" data-prog="100">ğŸ“ Quiz</button>
  <button class="sec-tab" data-sec="sh" data-prog="100">ğŸ† GeÃ§miÅŸ</button>
</nav>

<main class="main">

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• S1: TÃœYlÃ¼ HÃ¼creli LÃ¶semi â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page active" id="s1">
  <p class="page-tag">BÃ¶lÃ¼m 01 / 06</p>
  <h1 class="page-h1">TÃ¼ylÃ¼ <em>HÃ¼creli</em><br>LÃ¶semi (HCL)</h1>
  <p class="page-intro">
    Nadir bir matÃ¼r B-hÃ¼creli lenfoproliferatif hastalÄ±k. Sitoplazma uzantÄ±larÄ± olan ("tÃ¼ylÃ¼") lenfositler, masif splenomegali ve pansitopeni ile karakterizedir. <strong>BRAF V600E mutasyonu</strong> tanÄ±mlayÄ±cÄ± genetik Ã¶zelliktir.<sup class="ref">[1]</sup>
  </p>

  <!-- Case Box -->
  <div class="case-box">
    <div class="case-q"><strong>Vaka:</strong> 55 yaÅŸÄ±nda erkek hasta, kan baÄŸÄ±ÅŸlamak iÃ§in gittiÄŸi merkezde hemoglobinin dÃ¼ÅŸÃ¼k olmasÄ± nedeniyle geri Ã§evrilmiÅŸ. Belirgin ÅŸikayet yok; geÃ§en yÄ±l 2 kez pnÃ¶moni geÃ§irip antibiyotik kullanmÄ±ÅŸ. Fizik muayenede dalak alt kutbu 6 cm palpe ediliyor. Periferik yayma sonucu alÄ±nmÄ±ÅŸtÄ±r.</div>
    <div class="case-findings">
      <span class="case-finding" style="background:var(--red-d);border-color:var(--red);color:var(--red)">Hgb â†“</span>
      <span class="case-finding" style="background:var(--red-d);border-color:var(--red);color:var(--red)">Trombosit â†“</span>
      <span class="case-finding" style="background:var(--amber-d);border-color:var(--amber);color:var(--amber)">LÃ¶kosit â†‘ (veya â†“)</span>
      <span class="case-finding" style="background:var(--red-d);border-color:var(--red);color:var(--red)">RetikÃ¼lositoisi â†“</span>
      <span class="case-finding" style="background:var(--purple-d);border-color:var(--purple);color:var(--purple)">Masif splenomegali</span>
      <span class="case-finding" style="background:var(--teal-d);border-color:var(--teal);color:var(--teal)">Periferik tÃ¼ylÃ¼ hÃ¼creler</span>
      <span class="case-finding" style="background:var(--blue-d);border-color:var(--blue);color:var(--blue)">Monositopeni</span>
    </div>
  </div>

  <div class="info-box teal">
    <strong>ğŸ”‘ Ã–nemli:</strong> Pansitopeni + masif splenomegali kombinasyonunda akla gelmesi gereken iki ana hematolojik hastalÄ±k grubu: <strong>Miyeloproliferatif hastalÄ±klar</strong> ve <strong>Lenfoproliferatif hastalÄ±klar</strong>. HCL bu tablonun klasik Ã¶rneÄŸidir.<sup class="ref">[1,2]</sup>
  </div>

  <div class="sec-title">TanÄ± BulgularÄ±</div>

  <!-- Periferik yayma SVG diagram -->
  <div class="tbl-wrap" style="padding:0">
    <div style="padding:14px 16px 0;font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d)">Åekil 1. Periferik Yayma â€” TÃ¼ylÃ¼ HÃ¼cre Morfolojisi</div>
    <div style="padding:20px;display:flex;justify-content:center">
      <svg viewBox="0 0 400 180" style="width:min(400px,100%);height:auto">
        <!-- Background cells -->
        <circle cx="60" cy="90" r="18" fill="#111822" stroke="#1e2d40" stroke-width="1"/>
        <circle cx="60" cy="90" r="10" fill="#192030"/>
        <circle cx="130" cy="50" r="16" fill="#111822" stroke="#1e2d40" stroke-width="1"/>
        <circle cx="130" cy="50" r="9" fill="#192030"/>
        <circle cx="340" cy="70" r="14" fill="#111822" stroke="#1e2d40" stroke-width="1"/>
        <circle cx="340" cy="70" r="7" fill="#192030"/>
        <!-- MAIN hairy cell -->
        <g transform="translate(220,90)">
          <!-- Cytoplasmic projections (hairy) -->
          <line x1="0" y1="-22" x2="-4" y2="-32" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="0" y1="-22" x2="4" y2="-32" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="18" y1="-12" x2="26" y2="-18" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="18" y1="-12" x2="29" y2="-6" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="18" y1="8" x2="28" y2="14" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="0" y1="22" x2="-4" y2="32" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="0" y1="22" x2="5" y2="32" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="-18" y1="8" x2="-28" y2="14" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="-18" y1="-12" x2="-28" y2="-18" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <line x1="-18" y1="-12" x2="-30" y2="-6" stroke="#3dd6c8" stroke-width="1.2" stroke-linecap="round"/>
          <!-- Cell body -->
          <circle r="22" fill="#0e1520" stroke="#3dd6c8" stroke-width="1.8"/>
          <!-- Nucleus (oval, off-center) -->
          <ellipse cx="2" cy="0" rx="14" ry="12" fill="#192030" stroke="#5a9cf5" stroke-width="1.2"/>
          <!-- Cytoplasm label -->
          <text y="42" fill="#3dd6c8" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">TÃ¼ylÃ¼ HÃ¼cre</text>
          <text y="53" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">SaÃ§ak Ã§Ä±kÄ±ntÄ±lar</text>
        </g>
        <!-- Monocyte zero label -->
        <text x="200" y="165" fill="#5c7a95" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Monositopeni: Periferik yaymada monosit gÃ¶rÃ¼lmez â†’ HCL iÃ§in Ã§ok tipik</text>
        <!-- Arrows -->
        <line x1="240" y1="68" x2="256" y2="60" stroke="#1e2d40" stroke-width="1"/>
        <text x="262" y="57" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace">Oval nÃ¼kleus</text>
      </svg>
    </div>
  </div>

  <div class="card-row">
    <div class="card">
      <div class="card-top teal"></div>
      <div class="card-icon">ğŸ§¬</div>
      <div class="card-lbl">Patognomonik Mutasyon</div>
      <div class="card-val">BRAF V600E</div>
      <div class="card-desc">Klasik HCL'de vakalarÄ±n ~%100'Ã¼nde tespit edilir. RAF-MEK-ERK sinyal yolaÄŸÄ±nÄ±n konstitÃ¼tif aktivasyonuna neden olur. HCL-v (varyant)'ta yoktur.<sup class="ref">[1,3]</sup></div>
    </div>
    <div class="card">
      <div class="card-top purple"></div>
      <div class="card-icon">ğŸ”¬</div>
      <div class="card-lbl">Kemik Ä°liÄŸi Biyopsisi</div>
      <div class="card-val">Dry Tap âš ï¸</div>
      <div class="card-desc">Aspirasyon yapÄ±lamaz â†’ <strong>Dry tap</strong>. Kemik iliÄŸi fibrozisi nedeniyle aspirasyon boÅŸ gelir. Bu bulgu HCL iÃ§in son derece karakteristiktir.<sup class="ref">[2]</sup></div>
    </div>
    <div class="card">
      <div class="card-top blue"></div>
      <div class="card-icon">ğŸ’‰</div>
      <div class="card-lbl">AkÄ±m Sitometrisi</div>
      <div class="card-val">CD11c, CD25, CD103</div>
      <div class="card-desc">CD19, CD20 (yÃ¼ksek dÃ¼zey), CD11c, CD25, CD103 pozitif. ANXA1 (Annexin A1) boyamasÄ± pozitif â†’ HCL'ye Ã¶zgÃ¼.<sup class="ref">[1,2]</sup></div>
    </div>
    <div class="card">
      <div class="card-top red"></div>
      <div class="card-icon">ğŸ“‰</div>
      <div class="card-lbl">Tipik Hemogram Bulgusu</div>
      <div class="card-val">Monositopeni</div>
      <div class="card-desc">Periferik yaymada monosit <strong>sÄ±fÄ±ra</strong> yakÄ±n. HCL iÃ§in son derece spesifik bir bulgudur. Pansitopeni olmayÄ±p lokositoz da gÃ¶rÃ¼lebilir.<sup class="ref">[1]</sup></div>
    </div>
  </div>

  <div class="sec-title">Tedavi AlgoritmasÄ±</div>

  <div class="algo">
    <div class="algo-row">
      <div class="algo-conn"><div class="algo-dot"></div><div class="algo-line"></div></div>
      <div class="algo-content">
        <div class="algo-lbl">1. Basamak â€” Standart Tedavi</div>
        <div class="algo-txt"><code>Kladribin</code> (2-CdA) Â± Rituksimab â†’ Tek kÃ¼r ile derin tam remisyon (%80-95). Kladribin, ease of administration ve favorable toxicity profili nedeniyle ilk tercih.<sup class="ref">[2,4]</sup></div>
        <div class="algo-note">Pentostation alternatiftir; kladribin ile Ã§apraz direnÃ§ yoktur</div>
      </div>
    </div>
    <div class="algo-row">
      <div class="algo-conn"><div class="algo-dot"></div><div class="algo-line"></div></div>
      <div class="algo-content">
        <div class="algo-lbl">YoÄŸun Ä°mmÃ¼nsÃ¼presyon Riski Varsa (YaÅŸlÄ±/Enfeksiyonlu)</div>
        <div class="algo-txt"><code>Vemurafenib</code> veya <code>Dabrafenib</code> (BRAF inhibitÃ¶rleri) Â± Rituksimab/Obinutuzumab. Kemoterapisiz alternatif.<sup class="ref">[3,4]</sup></div>
        <div class="algo-note">NCCN 2025: Off-label ama klinik pratikte yaygÄ±n kullanÄ±m</div>
      </div>
    </div>
    <div class="algo-row">
      <div class="algo-conn"><div class="algo-dot" style="border-color:var(--amber)"></div><div class="algo-line" style="background:linear-gradient(var(--amber),transparent)"></div></div>
      <div class="algo-content" style="border-color:rgba(232,162,74,.3)">
        <div class="algo-lbl" style="color:var(--amber)">NÃ¼ks / Refrakter HastalÄ±k</div>
        <div class="algo-txt">Kladribin Â± Rituksimab yeniden Â· BRAF inhibitÃ¶rleri (Vemurafenib, Dabrafenib + Trametinib) Â· <code>Moksetumomab pasudotoks</code> (CD22 hedefli immÃ¼notoksin) Â· Venetoklaks<sup class="ref">[3,4]</sup></div>
        <div class="algo-note" style="color:rgba(232,162,74,.6)">âš ï¸ Moksetumomab ABD pazarÄ±ndan Ã§ekildi (2022); bazÄ± Ã¼lkelerde hÃ¢lÃ¢ eriÅŸilebilir</div>
      </div>
    </div>
  </div>

  <div class="info-box amber">
    <strong>âš ï¸ Pansitopeni â‰  Mutlaka HCL!</strong> HCL'de pansitopeni gÃ¶zÃ¼kse de <strong>lÃ¶kositoz</strong> da olabilir. Lokositoz + masif splenomegali + periferik tÃ¼ylÃ¼ hÃ¼creler â†’ HCL tanÄ±sÄ±nÄ± dÄ±ÅŸlamaz. Pansitopeni bir kural deÄŸildir.<sup class="ref">[1]</sup>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[1]</span> Falini B, Tiacci E. Hairy-Cell Leukemia. <em>N Engl J Med</em>. 2024;391(14):1328â€“1341.</li>
      <li><span class="rn">[2]</span> Grever MR, et al. Consensus guidelines for diagnosis and management of HCL. <em>Blood</em>. 2017;129(5):553â€“560.</li>
      <li><span class="rn">[3]</span> NCCN Guidelines: Hairy Cell Leukemia. Version 1.2025. September 26, 2024.</li>
      <li><span class="rn">[4]</span> Falini B, Tiacci E. BRAF V600E mutation in hairy cell leukemia. <em>Blood</em>. 2016;128(15):1918â€“1927.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <span></span>
    <button class="btn-next-sec" onclick="goSection('s2')">KLL &amp; Akut LÃ¶semiler â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• S2: KLL & AKUT LÃ–SEMÄ°LER â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s2">
  <p class="page-tag">BÃ¶lÃ¼m 02 / 06</p>
  <h1 class="page-h1">KLL &amp; <em>Akut</em><br>LÃ¶semiler</h1>
  <p class="page-intro">
    Kronik Lenfositik LÃ¶semi (KLL) eriÅŸkinlerin en sÄ±k lÃ¶semisidir. Akut lÃ¶semiler ise blast proliferasyonu ile karakterizedir. Periferik yayma bulgularÄ± ayÄ±rÄ±cÄ± tanÄ±da kritik rol oynar.
  </p>

  <div class="sec-title">Kronik Lenfositik LÃ¶semi (KLL / CLL)</div>

  <div class="case-box">
    <div class="case-q"><strong>Tipik Vaka:</strong> 65-75 yaÅŸÄ±nda hasta, halsizlik-yorgunluk ÅŸikayetiyle baÅŸvuruyor. Lenfosit sayÄ±sÄ± 20.000-100.000 arasÄ±. Periferik yaymada ezilmiÅŸ lenfositler (smudge/smear hÃ¼creleri). Dalak bÃ¼yÃ¼mesi olabilir.</div>
    <div class="case-findings">
      <span class="case-finding" style="background:var(--blue-d);border-color:var(--blue);color:var(--blue)">Lenfositoz (â‰¥5000/ÂµL)</span>
      <span class="case-finding" style="background:var(--purple-d);border-color:var(--purple);color:var(--purple)">Smudge / Smear HÃ¼creleri</span>
      <span class="case-finding" style="background:var(--teal-d);border-color:var(--teal);color:var(--teal)">Atipik lenfosit (Downey hÃ¼cresi)</span>
    </div>
  </div>

  <div class="tbl-wrap" style="padding:0">
    <div style="padding:14px 16px 0;font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d)">Åekil 2. KLL Periferik YaymasÄ±</div>
    <div style="padding:18px;display:flex;justify-content:center">
      <svg viewBox="0 0 400 140" style="width:min(400px,100%);height:auto">
        <!-- Normal lymphocyte -->
        <g transform="translate(80,70)">
          <circle r="20" fill="#0e1520" stroke="#5a9cf5" stroke-width="1.5"/>
          <circle cx="0" cy="0" r="14" fill="#192030" stroke="#3dd6c8" stroke-width="1"/>
          <text y="34" fill="#5a9cf5" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Normal</text>
          <text y="44" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">Lenfosit</text>
        </g>
        <!-- Smudge cell 1 -->
        <g transform="translate(200,70)">
          <ellipse rx="26" ry="12" fill="#0e1520" stroke="#e85c5c" stroke-width="1.5"/>
          <path d="M-20,0 Q-10,-8 0,0 Q10,8 20,0" fill="none" stroke="#e8a24a" stroke-width="1"/>
          <path d="M-15,-6 Q0,0 15,-4" fill="none" stroke="#e8a24a" stroke-width="1"/>
          <text y="26" fill="#e85c5c" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Smudge</text>
          <text y="36" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">EzilmiÅŸ lenfosit</text>
        </g>
        <!-- Smudge cell 2 -->
        <g transform="translate(310,65)">
          <ellipse rx="30" ry="8" fill="#0e1520" stroke="#e85c5c" stroke-width="1.2" opacity="0.7"/>
          <path d="M-22,0 Q-8,-5 8,2 Q18,-4 26,0" fill="none" stroke="#e8a24a" stroke-width="1"/>
          <text y="24" fill="#e85c5c" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Smear</text>
          <text y="34" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">HÃ¼cresi</text>
        </g>
        <text x="200" y="120" fill="#5c7a95" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">KLL'de mekanik baskÄ±yla oluÅŸan ezilmiÅŸ lenfositler â€” preparasyona Ã¶zgÃ¼ artefakt</text>
      </svg>
    </div>
  </div>

  <div class="card-row">
    <div class="card">
      <div class="card-top blue"></div>
      <div class="card-icon">ğŸ‘´</div>
      <div class="card-lbl">En SÄ±k GÃ¶rÃ¼lme</div>
      <div class="card-val">â‰¥65 YaÅŸ</div>
      <div class="card-desc">EriÅŸkinlerin en sÄ±k kronik lÃ¶semisi. YaÅŸlÄ± hasta + lenfositoz + smudge hÃ¼cresi = KLL tanÄ±sÄ±nÄ± dÃ¼ÅŸÃ¼n.<sup class="ref">[5]</sup></div>
    </div>
    <div class="card">
      <div class="card-top purple"></div>
      <div class="card-icon">ğŸ’Š</div>
      <div class="card-lbl">Tedavi Hedefi</div>
      <div class="card-val">BTK inhibitÃ¶rleri</div>
      <div class="card-desc"><strong>Ä°brutinib</strong> (Bruton kinaz inhibitÃ¶rÃ¼) KLL'de birincil tedavide kullanÄ±lÄ±r. Ofatumumab (CD20) ve Venetoklaks (BCL-2) diÄŸer seÃ§enekler.<sup class="ref">[5]</sup></div>
    </div>
    <div class="card">
      <div class="card-top teal"></div>
      <div class="card-icon">ğŸ”¬</div>
      <div class="card-lbl">Ä°nfeksiyÃ¶z Mono AyÄ±rÄ±cÄ± TanÄ±</div>
      <div class="card-val">EBV</div>
      <div class="card-desc">Splenomegali + atipik lenfositoz + ateÅŸ; faranjit ve tonsil bÃ¼yÃ¼mesi beklenir. Downey hÃ¼cresi = atipik lenfosit.</div>
    </div>
  </div>

  <div class="sec-title">Akut LÃ¶semiler â€” Periferik Yayma &amp; TanÄ±</div>

  <div class="tbl-wrap">
    <div class="tbl-cap">Tablo 1. LÃ¶semi TÃ¼rlerinin Periferik Yayma KarÅŸÄ±laÅŸtÄ±rmasÄ±</div>
    <table>
      <thead><tr><th>HastalÄ±k</th><th>YaÅŸ Grubu</th><th>Periferik Bulgu</th><th>TanÄ± Ä°pucu</th></tr></thead>
      <tbody>
        <tr>
          <td><strong>HCL</strong></td>
          <td class="mono">Orta yaÅŸ</td>
          <td>TÃ¼ylÃ¼ hÃ¼creler, saÃ§ak Ã§Ä±kÄ±ntÄ±lar</td>
          <td>Dry tap, BRAF V600E, CD25/103<sup class="ref">[1]</sup></td>
        </tr>
        <tr>
          <td><strong>KLL</strong></td>
          <td class="mono">â‰¥65 yaÅŸ</td>
          <td>Smudge/smear hÃ¼creleri, kÃ¼Ã§Ã¼k matÃ¼r lenfositler</td>
          <td>CD5+CD23+CD20(dim), lenfositoz<sup class="ref">[5]</sup></td>
        </tr>
        <tr>
          <td><strong>ALL (Akut)</strong></td>
          <td class="mono">Ã‡ocuk &gt; eriÅŸkin</td>
          <td>Blastlar (geniÅŸ nÃ¼kleus, dar sitoplazma)</td>
          <td>TdT+, CD10+, acil KT baÅŸlanÄ±r<sup class="ref">[6]</sup></td>
        </tr>
        <tr>
          <td><strong>MDS</strong></td>
          <td class="mono">YaÅŸlÄ±</td>
          <td>Dispazik hÃ¼creler, sitopeni</td>
          <td>Pansitopeni ama lÃ¶kositoz beklenmez<sup class="ref">[5]</sup></td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="info-box purple">
    <strong>ğŸ“ SÄ±nav Ä°pucu â€” Periferik Yayma:</strong> Periferik yaymayÄ± gÃ¶rÃ¼p "bu nedir?" diye sormazlar; vakayÄ± okuyup yaymayÄ± <em>destekleyici bulgu</em> olarak kullanÄ±n.
    <strong>Smudge hÃ¼cresi</strong> = KLL | <strong>TÃ¼ylÃ¼ hÃ¼cre</strong> = HCL | <strong>Blast</strong> = Akut lÃ¶semi.
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[1]</span> Falini B, Tiacci E. Hairy-Cell Leukemia. <em>N Engl J Med</em>. 2024;391(14):1328â€“1341.</li>
      <li><span class="rn">[5]</span> Wierda WG, et al. NCCN Guidelines: CLL/SLL. Version 2.2025.</li>
      <li><span class="rn">[6]</span> Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. <em>N Engl J Med</em>. 2015;373:1541â€“1552.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s1')">â† TÃ¼ylÃ¼ HÃ¼cre</button>
    <button class="btn-next-sec" onclick="goSection('s3')">CD20 / CD30 / CD33 â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• S3: CD20/30/33 â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s3">
  <p class="page-tag">BÃ¶lÃ¼m 03 / 06</p>
  <h1 class="page-h1">Monoklonal<br><em>Antikorlar</em> â€” CD20/30/33</h1>
  <p class="page-intro">
    B-hÃ¼creli lenfoma ve lÃ¶semilerin yÃ¼zeyinde eksprese olan spesifik antijenler, monoklonal antikorcular iÃ§in hedef oluÅŸturur. Bu bÃ¶lÃ¼mde en klinik Ã¶neme sahip Ã¼Ã§ antijen ve ilgili ajanlar ele alÄ±nmaktadÄ±r.
  </p>

  <!-- Antigen-antibody visual -->
  <div class="tbl-wrap" style="padding:0">
    <div style="padding:14px 16px 0;font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d)">Åekil 3. Hedefe YÃ¶nelik Antikor MekanizmasÄ±</div>
    <div style="padding:20px;display:flex;justify-content:center">
      <svg viewBox="0 0 500 160" style="width:min(500px,100%);height:auto">
        <!-- Tumor cell -->
        <circle cx="100" cy="80" r="45" fill="#0e1520" stroke="#1e2d40" stroke-width="1.5"/>
        <text x="100" y="76" fill="#5a9cf5" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">TÃ¼mÃ¶r</text>
        <text x="100" y="88" fill="#5a9cf5" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">HÃ¼cresi</text>
        <!-- Antigens on surface -->
        <circle cx="100" cy="35" r="6" fill="#3dd6c8" stroke="#3dd6c8" stroke-width="1"/>
        <text x="100" y="28" fill="#3dd6c8" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">CD20</text>
        <circle cx="130" cy="55" r="5" fill="#b07ef5" stroke="#b07ef5" stroke-width="1"/>
        <text x="145" y="51" fill="#b07ef5" font-size="8" font-family="DM Mono,monospace">CD30</text>
        <circle cx="70" cy="55" r="5" fill="#e8a24a" stroke="#e8a24a" stroke-width="1"/>
        <text x="44" y="51" fill="#e8a24a" font-size="8" font-family="DM Mono,monospace">CD33</text>
        <!-- Antibody Y shape -->
        <g transform="translate(260,80)">
          <line x1="0" y1="20" x2="0" y2="-5" stroke="#3dd6c8" stroke-width="2.5" stroke-linecap="round"/>
          <line x1="0" y1="-5" x2="-16" y2="-25" stroke="#3dd6c8" stroke-width="2.5" stroke-linecap="round"/>
          <line x1="0" y1="-5" x2="16" y2="-25" stroke="#3dd6c8" stroke-width="2.5" stroke-linecap="round"/>
          <circle cx="-20" cy="-28" r="6" fill="#3dd6c8" opacity="0.8"/>
          <circle cx="20" cy="-28" r="6" fill="#3dd6c8" opacity="0.8"/>
          <text y="36" fill="#3dd6c8" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Rituksimab</text>
        </g>
        <!-- Arrow -->
        <line x1="155" y1="80" x2="230" y2="80" stroke="#1e2d40" stroke-width="1.5" stroke-dasharray="4,3"/>
        <!-- Effects -->
        <g transform="translate(390,80)">
          <circle r="32" fill="#0e1520" stroke="#4ecb87" stroke-width="1.2"/>
          <text y="-5" fill="#4ecb87" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">CDC /</text>
          <text y="7" fill="#4ecb87" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">ADCC /</text>
          <text y="19" fill="#4ecb87" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Apoptoz</text>
        </g>
        <line x1="306" y1="80" x2="355" y2="80" stroke="#4ecb87" stroke-width="1.5"/>
      </svg>
    </div>
  </div>

  <div class="sec-title">CD20 â€” Anti-B HÃ¼cre AntikorlarÄ±</div>
  <div class="drug-grid">
    <div class="drug-card cd20">
      <div class="drug-name">Rituksimab</div>
      <div class="drug-target"><code>CD20</code> <span>â†’</span> Kimerik monoklonal antikor</div>
      <div class="drug-indication">B hÃ¼creli NHL, KLL, RA. KLL + lenfoma tedavisinde temel ajan. HCL'de kladribin ile kombinasyonla kullanÄ±lÄ±r.</div>
      <div class="drug-note exam">â­ Onlarca sÄ±nav sorusunda geÃ§miÅŸtir. Temel ajan olarak ezberleyin.</div>
    </div>
    <div class="drug-card cd20">
      <div class="drug-name">Ofatumumab</div>
      <div class="drug-target"><code>CD20</code> <span>â†’</span> Tam insan antikoru</div>
      <div class="drug-indication">KLL (Ã¶zellikle fludarabin refrakter). Tam insan antikoru olduÄŸundan alerji riski daha dÃ¼ÅŸÃ¼k.</div>
    </div>
    <div class="drug-card cd20">
      <div class="drug-name">Obinutuzumab</div>
      <div class="drug-target"><code>CD20</code> <span>â†’</span> 3. nesil glikoengineer antikor</div>
      <div class="drug-indication">KLL, folikÃ¼ler lenfoma. ArtmÄ±ÅŸ ADCC aktivitesi. HCL'de BRAF inhibitÃ¶rleriyle kombinasyonda kullanÄ±labilir.<sup class="ref">[3]</sup></div>
    </div>
  </div>

  <div class="sec-title">CD30 â€” Hodgkin &amp; ALCL</div>
  <div class="drug-grid">
    <div class="drug-card cd30">
      <div class="drug-name">Brentuximab Vedotin</div>
      <div class="drug-target"><code>CD30</code> <span>â†’</span> ADC (antikor-ilaÃ§ konjugatÄ±)</div>
      <div class="drug-indication">Hodgkin lenfoma, Anaplastik BÃ¼yÃ¼k HÃ¼creli Lenfoma (ALCL), Mikozis Fungoides. CD30 ekspresyonlu tÃ¼mÃ¶rlerde etkili.</div>
      <div class="drug-note tip">âš ï¸ NÃ¶rotoksisite (periferik nÃ¶ropati) ana yan etkisi.<sup class="ref">[7]</sup></div>
    </div>
  </div>

  <div class="sec-title">CD33 â€” Akut Miyeloid LÃ¶semi</div>
  <div class="drug-grid">
    <div class="drug-card cd33">
      <div class="drug-name">Gemtuzumab Ozogamicin</div>
      <div class="drug-target"><code>CD33</code> <span>â†’</span> ADC (Calicheamicin konjugatÄ±)</div>
      <div class="drug-indication">AML (CD33 pozitif). Yeniden pazara girmiÅŸtir (2017).</div>
      <div class="drug-note warn">ğŸ”´ Ciddi hepatotoksisite (VOD â€” Veno-oklusif hastalÄ±k) yapabilir. Ä°zlemde LFT takibi ÅŸart.<sup class="ref">[8]</sup></div>
    </div>
  </div>

  <div class="info-box blue">
    <strong>ğŸ“Œ CD52 â€” Alemtuzumab:</strong> T-hÃ¼creli periferik lenfoma ve KLL'de kullanÄ±lan CD52 hedefli antikor. Mikozis fungoides gibi deri T-hÃ¼creli lenfomalarda (CTCl) mÃ¼kemmel yanÄ±t.<sup class="ref">[7]</sup>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[3]</span> NCCN Guidelines: Hairy Cell Leukemia. Version 1.2025.</li>
      <li><span class="rn">[7]</span> Younes A, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma. <em>Lancet Oncol</em>. 2013;14:1208â€“1219.</li>
      <li><span class="rn">[8]</span> Castaigne S, et al. Gemtuzumab ozogamicin in AML. <em>Lancet Oncol</em>. 2012;13:321â€“332.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s2')">â† KLL & Akut</button>
    <button class="btn-next-sec" onclick="goSection('s4')">HER2 Â· VEGF Â· EGFR â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• S4: HER2 Â· VEGF Â· EGFR â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s4">
  <p class="page-tag">BÃ¶lÃ¼m 04 / 06</p>
  <h1 class="page-h1">HER2 Â· VEGF Â·<br><em>EGFR</em> Hedeftedavileri</h1>
  <p class="page-intro">
    Solid tÃ¼mÃ¶rlerde en sÄ±k kullanÄ±lan hedefe yÃ¶nelik biyolojik ilaÃ§lar; meme kanseri, kolorektal kanser ve akciÄŸer kanseri tedavilerinde devrim yaratmÄ±ÅŸtÄ±r. Her hedef iÃ§in <strong>zorunlu biomarker testini</strong> Ã¶ÄŸrenmek kritiktir.
  </p>

  <div class="sec-title">HER2 (ErbB-2) â€” Meme Kanseri</div>
  <div class="drug-grid">
    <div class="drug-card her2">
      <div class="drug-name">Trastuzumab (Herceptin)</div>
      <div class="drug-target"><code>HER2</code> <span>â†’</span> EkstraselÃ¼ler domain antagonisti</div>
      <div class="drug-indication">HER2 pozitif meme kanseri ve mide/gastroÃ¶zofageal kavÅŸak kanseri. ER/PR negatif, HER2 pozitif hastalarda ilk tercih.</div>
      <div class="drug-note warn">âš ï¸ Kardiyotoksisite! EF takibi ÅŸart. Antrasiklin ile kombinde risk artar.<sup class="ref">[9]</sup></div>
    </div>
    <div class="drug-card her2">
      <div class="drug-name">Lapatinib</div>
      <div class="drug-target"><code>HER2 + EGFR</code> <span>â†’</span> Ä°ntraselÃ¼ler tirozin kinaz inhibitÃ¶rÃ¼</div>
      <div class="drug-indication">HER2 pozitif meme kanseri (oral). Trastuzumab'Ä±n intraselÃ¼ler Ã§alÄ±ÅŸan versiyonu. Beyin metastazÄ±nda daha etkin (kan-beyin bariyerini geÃ§er).</div>
      <div class="drug-note info">ğŸ’¡ Trastuzumab = ekstrasellÃ¼ler | Lapatinib = intrasellÃ¼ler kÃ¼Ã§Ã¼k molekÃ¼l inhibitÃ¶r.</div>
    </div>
  </div>

  <div class="sec-title">VEGF â€” VaskÃ¼ler Hedefli Tedavi</div>
  <div class="drug-grid">
    <div class="drug-card vegf">
      <div class="drug-name">Bevacizumab (Avastin)</div>
      <div class="drug-target"><code>VEGF-A</code> <span>â†’</span> Anti-anjiogenez monoklonal antikor</div>
      <div class="drug-indication">Kolorektal kanser (1. ve 2. basamak), glioblastom, NSCLC, renal hÃ¼creli kanser, serviks kanseri.</div>
      <div class="drug-note tip">ğŸ¯ Kolorektal kanserde en sÄ±k sorulmasÄ± beklenen ajan. TÃ¼mÃ¶r anjiogenezini baskÄ±lar.<sup class="ref">[10]</sup></div>
    </div>
  </div>

  <div class="sec-title">EGFR (HER1) â€” Kolorektal &amp; AkciÄŸer</div>

  <!-- KRAS pathway visual -->
  <div class="tbl-wrap" style="padding:0">
    <div style="padding:14px 16px 0;font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d)">Åekil 4. Setuksimab'da KRAS Wild Type ZorunluluÄŸu</div>
    <div style="padding:18px;overflow-x:auto">
      <div class="pathway">
        <!-- Cetuximab blocks EGFR -->
        <div class="pway-node pway-blocked">
          <div class="pway-icon" style="border-color:var(--green);background:var(--green-d)">ğŸ’Š</div>
          <div class="pway-lbl">Setuksimab<br>(Cetuximab)</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--green);background:var(--green-d)">ğŸ“¡</div>
          <div class="pway-lbl">EGFR<br>(bloke)</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--teal);background:var(--teal-d)">ğŸ§¬</div>
          <div class="pway-lbl">RAS/KRAS<br>(Wild Type âœ“)</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--blue);background:var(--blue-d)">âš¡</div>
          <div class="pway-lbl">RAF-MEK<br>ERK Sinyal</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--red);background:var(--red-d)">âŒ</div>
          <div class="pway-lbl">Proliferasyon<br>Durur</div>
        </div>
      </div>
      <div style="font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d);margin-top:8px;text-align:center">âš ï¸ KRAS mutasyonu varsa â†’ EGFR bloke olsa dahi RAS aÅŸaÄŸÄ± sinyal devam eder â†’ Setuksimab iÅŸe yaramaz</div>
    </div>
  </div>

  <div class="drug-grid">
    <div class="drug-card egfr">
      <div class="drug-name">Setuksimab (Cetuximab)</div>
      <div class="drug-target"><code>EGFR</code> <span>â†’</span> Anti-EGFR monoklonal antikor</div>
      <div class="drug-indication">KRAS <strong>wild type</strong> kolorektal kanser. KRAS mutasyonu varsa verilmemelidir.</div>
      <div class="drug-note warn">âš ï¸ Ã–lÃ¼mcÃ¼l hipomagnezemiye yol aÃ§abilir (EGFR inhibitÃ¶rÃ¼ sÄ±nÄ±f etkisi). Yandal uzmanlÄ±k sÄ±navÄ±nda sorulmuÅŸtur!<sup class="ref">[10]</sup></div>
    </div>
    <div class="drug-card egfr">
      <div class="drug-name">Erlotinib / Gefitinib / Afatinib</div>
      <div class="drug-target"><code>EGFR</code> <span>â†’</span> Tirozin kinaz inhibitÃ¶rÃ¼ (TKÄ°)</div>
      <div class="drug-indication">EGFR mutasyonu pozitif kÃ¼Ã§Ã¼k hÃ¼cre dÄ±ÅŸÄ± akciÄŸer kanseri (KHDAK). EGFR exon 19/21 mutasyonlarÄ±nda standart birinci basamak.<sup class="ref">[11]</sup></div>
      <div class="drug-note exam">â­ Son yandal dahiliye sÄ±navÄ±nda: EGFR mutasyonu olan akciÄŸer kanseri â†’ Erlotinib/Afatinib soruldu.</div>
    </div>
  </div>

  <div class="info-box red">
    <strong>ğŸ”´ EGFR Monoklonal Antikorlar (Setuksimab) â€” Hipomagnezemisi:</strong> EGFR, renal magnezyum geri emiliminde rol oynar. EGFR blokajÄ± â†’ renal magnezyum kaybÄ± â†’ <strong>hipomagnezemiye yol aÃ§ar</strong>. Ã–lÃ¼mcÃ¼l olabilir. Mg takibi zorunludur.<sup class="ref">[10]</sup>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[9]</span> Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody (Trastuzumab) for HER2-overexpressing breast cancer. <em>N Engl J Med</em>. 2001;344:783â€“792.</li>
      <li><span class="rn">[10]</span> Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <em>N Engl J Med</em>. 2009;360:1408â€“1417.</li>
      <li><span class="rn">[11]</span> Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. <em>N Engl J Med</em>. 2009;361:947â€“957.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s3')">â† CD20/30/33</button>
    <button class="btn-next-sec" onclick="goSection('s5')">Checkpoint Ä°nhibitÃ¶rleri â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• S5: CHECKPOINT â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s5">
  <p class="page-tag">BÃ¶lÃ¼m 05 / 06</p>
  <h1 class="page-h1">Ä°mmÃ¼n Kontrol NoktasÄ±<br><em>Ä°nhibitÃ¶rleri</em></h1>
  <p class="page-intro">
    CTLA-4, PD-1 ve PD-L1 blokajÄ±; tÃ¼mÃ¶rÃ¼n immÃ¼n kaÃ§Ä±ÅŸ mekanizmasÄ±nÄ± tersine Ã§evirerek kalÄ±cÄ± antitÃ¼mÃ¶r yanÄ±t oluÅŸturur. OtoimmÃ¼n yan etkiler bu sÄ±nÄ±fÄ±n en kritik klinik sorunu ve sÄ±nav konusudur.
  </p>

  <!-- Mechanism visual -->
  <div class="tbl-wrap" style="padding:0">
    <div style="padding:14px 16px 0;font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d)">Åekil 5. Checkpoint Ä°nhibitÃ¶rÃ¼ MekanizmasÄ±</div>
    <div style="padding:20px;display:flex;justify-content:center">
      <svg viewBox="0 0 500 170" style="width:min(500px,100%);height:auto">
        <!-- T cell -->
        <circle cx="110" cy="85" r="42" fill="#0e1520" stroke="#5a9cf5" stroke-width="1.5"/>
        <text x="110" y="81" fill="#5a9cf5" font-size="10" font-family="DM Mono,monospace" text-anchor="middle">T HÃ¼cresi</text>
        <!-- PD-1 receptor -->
        <rect x="130" y="72" width="20" height="26" rx="4" fill="#192030" stroke="#e85c5c" stroke-width="1.5"/>
        <text x="140" y="89" fill="#e85c5c" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">PD-1</text>
        <!-- Tumor cell -->
        <circle cx="360" cy="85" r="42" fill="#0e1520" stroke="#e8a24a" stroke-width="1.5"/>
        <text x="360" y="81" fill="#e8a24a" font-size="10" font-family="DM Mono,monospace" text-anchor="middle">TÃ¼mÃ¶r</text>
        <text x="360" y="93" fill="#e8a24a" font-size="10" font-family="DM Mono,monospace" text-anchor="middle">HÃ¼cresi</text>
        <!-- PD-L1 on tumor -->
        <rect x="320" y="72" width="22" height="26" rx="4" fill="#192030" stroke="#e8a24a" stroke-width="1.5"/>
        <text x="331" y="89" fill="#e8a24a" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">PD-L1</text>
        <!-- Interaction blocked by drug -->
        <rect x="222" y="75" width="56" height="20" rx="6" fill="#b07ef5" opacity="0.18"/>
        <text x="250" y="88" fill="#b07ef5" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Pembrolizumab</text>
        <!-- Block arrows -->
        <line x1="152" y1="85" x2="218" y2="85" stroke="#e85c5c" stroke-width="1.2" stroke-dasharray="4,2"/>
        <line x1="280" y1="85" x2="318" y2="85" stroke="#e8a24a" stroke-width="1.2" stroke-dasharray="4,2"/>
        <!-- T cell activated -->
        <circle cx="110" cy="85" r="42" fill="none" stroke="#4ecb87" stroke-width="1" stroke-dasharray="6,4" opacity="0.6"/>
        <text x="250" y="135" fill="#5c7a95" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">PD-1/PD-L1 blokajÄ± â†’ T hÃ¼cresi aktive â†’ TÃ¼mÃ¶r hÃ¼cresi tanÄ±nÄ±r ve yok edilir</text>
        <text x="110" y="148" fill="#4ecb87" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">Aktive âœ“</text>
      </svg>
    </div>
  </div>

  <div class="drug-grid">
    <div class="drug-card checkpoint">
      <div class="drug-name">Ä°pilimumab</div>
      <div class="drug-target"><code>CTLA-4</code> <span>â†’</span> Anti-CTLA-4</div>
      <div class="drug-indication">Malin melanom, renal hÃ¼creli kanser. Ä°lk onaylanan checkpoint inhibitÃ¶rÃ¼ (2011).</div>
      <div class="drug-note warn">ğŸ”´ OtoimmÃ¼n hipofizit! Ä°pilimumab'Ä±n en karakteristik yan etkisidir. Ä°nsidans ~%3-6 (monoterapi), kombinasyonda %8-14.<sup class="ref">[12,13]</sup></div>
    </div>
    <div class="drug-card checkpoint">
      <div class="drug-name">Nivolumab</div>
      <div class="drug-target"><code>PD-1</code> <span>â†’</span> Anti-PD-1</div>
      <div class="drug-indication">Hodgkin lenfoma (CD30+), NSCLC, melanom, renal hÃ¼creli kanser, gastrik kanser. Hodgkin'de Ã§ok popÃ¼ler.</div>
      <div class="drug-note tip">Nivolumab + Ä°pilimumab kombinasyonu daha fazla irAE; hipofizit insidansÄ± ~%10-14.<sup class="ref">[13]</sup></div>
    </div>
    <div class="drug-card checkpoint">
      <div class="drug-name">Pembrolizumab</div>
      <div class="drug-target"><code>PD-1</code> <span>â†’</span> Anti-PD-1</div>
      <div class="drug-indication">Hodgkin lenfoma, melanom, NSCLC, MSI-H/dMMR kanserler, serviks kanseri. GeniÅŸ endikasyon.</div>
      <div class="drug-note exam">â­ Hodgkin lenfoma + anti-PD-1 = sÄ±nav klasiÄŸi. Hem Nivolumab hem Pembrolizumab sorulabilir.<sup class="ref">[7]</sup></div>
    </div>
    <div class="drug-card checkpoint">
      <div class="drug-name">Atezolizumab</div>
      <div class="drug-target"><code>PD-L1</code> <span>â†’</span> Anti-PD-L1</div>
      <div class="drug-indication">NSCLC (1. basamak), Ã¼rotelyal kanser, meme kanseri (triple-negatif). PD-L1 ekspresyonu yÃ¼ksek tÃ¼mÃ¶rlerde tercih.</div>
    </div>
    <div class="drug-card checkpoint">
      <div class="drug-name">Durvalumab</div>
      <div class="drug-target"><code>PD-L1</code> <span>â†’</span> Anti-PD-L1</div>
      <div class="drug-indication">KÃ¼Ã§Ã¼k hÃ¼cre dÄ±ÅŸÄ± ve kÃ¼Ã§Ã¼k hÃ¼creli akciÄŸer kanseri. EÅŸzamanlÄ± KRT sonrasÄ± konsolidasyon tedavisi.</div>
    </div>
  </div>

  <div class="sec-title">OtoimmÃ¼n Hipofizit â€” SÄ±nav Favorisi!</div>
  <div class="card-row">
    <div class="card">
      <div class="card-top red"></div>
      <div class="card-icon">ğŸ§ </div>
      <div class="card-lbl">Hangi Ä°laÃ§?</div>
      <div class="card-val">Ä°pilimumab (CTLA-4)</div>
      <div class="card-desc">Ä°pilimumab en sÄ±k hipofizit yapan checkpoint inhibitÃ¶rÃ¼dÃ¼r (%3-6 monoterapi, %8-14 kombinasyon).<sup class="ref">[12,13]</sup></div>
    </div>
    <div class="card">
      <div class="card-top amber"></div>
      <div class="card-icon">âš ï¸</div>
      <div class="card-lbl">Klinik Bulgu</div>
      <div class="card-val">Yorgunluk, BaÅŸaÄŸrÄ±sÄ±</div>
      <div class="card-desc">Ã–n hipofiz yetersizliÄŸi (adrenal, tiroid, gonadal eksen), hiponatremi. Ortalama baÅŸlangÄ±Ã§: tedaviden 2-3 ay sonra.<sup class="ref">[13]</sup></div>
    </div>
    <div class="card">
      <div class="card-top green"></div>
      <div class="card-icon">ğŸ’Š</div>
      <div class="card-lbl">Tedavi</div>
      <div class="card-val">Hormon Replasman</div>
      <div class="card-desc">Kortikosteroid replasman tedavisi (yetersizlik iÃ§in). YÃ¼ksek doz kortikosteroidin hipofiz fonksiyonunu geri kazandÄ±rdÄ±ÄŸÄ±na dair kanÄ±t yoktur.<sup class="ref">[14]</sup></div>
    </div>
  </div>

  <div class="info-box purple">
    <strong>ğŸ“ SÄ±nav NoktasÄ± â€” Ä°pilimumab ve OtoimmÃ¼n Hipofizit:</strong> Ä°pilimumab verilen bir melanom hastasÄ±nda <em>yorgunluk + baÅŸ aÄŸrÄ±sÄ± + hiponatremi</em> gÃ¶rÃ¼ldÃ¼ÄŸÃ¼nde â†’ otoimmÃ¼n hipofizit dÃ¼ÅŸÃ¼n. TSH, kortizol, ACTH, FSH/LH, testosteron bakÄ±n. Bu kombinasyon yandal uzmanlÄ±k sÄ±navÄ±nda sorulmuÅŸtur!<sup class="ref">[12,13]</sup>
  </div>

  <div class="accord">
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ’¡</span><span class="accord-title">ALK (Anaplastik Lenfoma Kinaz) Ä°nhibitÃ¶rleri â€” Krizotinib</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        <strong>Krizotinib</strong> bir ALK inhibitÃ¶rÃ¼dÃ¼r. ALK = Anaplastik Lenfoma Kinaz. Hangi tÃ¼mÃ¶rlerde pozitif? â‘  Anaplastik BÃ¼yÃ¼k HÃ¼creli Lenfoma (ALCL) â‘¡ KÃ¼Ã§Ã¼k hÃ¼creli dÄ±ÅŸÄ± akciÄŸer kanseri (KHDAK) â€” Ã¶zellikle adeno. Periferik T-hÃ¼creli lenfomalar arasÄ±nda prognozu en iyi olan; ALK+ ALCL'dir. ALK negatif olursa prognoz Ã§ok kÃ¶tÃ¼dÃ¼r.<sup class="ref">[7]</sup>
      </div>
    </div>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[7]</span> Younes A, et al. Brentuximab vedotin + ABVD/AVD for Hodgkin's lymphoma. <em>Lancet Oncol</em>. 2013;14:1208.</li>
      <li><span class="rn">[12]</span> Faje A, et al. Ipilimumab-induced hypophysitis. <em>J Clin Endocrinol Metab</em>. 2014;99:4078â€“4085.</li>
      <li><span class="rn">[13]</span> Zhao C, et al. Immune checkpoint inhibitorâ€“induced hypophysitis: incidence and patterns. <em>Front Oncol</em>. 2022;12:836859.</li>
      <li><span class="rn">[14]</span> Brahmer JR, et al. Management of immune-related adverse events (ASCO guideline update). <em>J Clin Oncol</em>. 2022;40:1206â€“1231.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s4')">â† HER2Â·VEGFÂ·EGFR</button>
    <button class="btn-next-sec" onclick="goSection('s6')">BRAF &amp; Ã–zel â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• S6: BRAF & Ã–ZEL â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s6">
  <p class="page-tag">BÃ¶lÃ¼m 06 / 06</p>
  <h1 class="page-h1">BRAF Ä°nhibitÃ¶rleri &amp;<br><em>Ã–zel Klinik Durumlar</em></h1>
  <p class="page-intro">
    BRAF inhibitÃ¶rleri melanom tedavisinin yanÄ± sÄ±ra HCL ve Langerhans hÃ¼creli histiyositozda da kullanÄ±lmaktadÄ±r. L-Asparaginaz ve Ä°rinotekan toksisiteleri klinik pratikte dikkat gerektiren Ã¶zel durumlardÄ±r.
  </p>

  <div class="sec-title">BRAF Ä°nhibitÃ¶rleri</div>

  <!-- BRAF pathway visual -->
  <div class="tbl-wrap" style="padding:0">
    <div style="padding:14px 16px 0;font-family:'DM Mono',monospace;font-size:9.5px;letter-spacing:1.8px;text-transform:uppercase;color:var(--txt-d)">Åekil 6. RAF-MEK-ERK YolaÄŸÄ± ve BRAF Ä°nhibitÃ¶r Etki NoktasÄ±</div>
    <div style="padding:18px;overflow-x:auto">
      <div class="pathway">
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--txt-d);background:var(--bg3)">ğŸ”¬</div>
          <div class="pway-lbl">RAS<br>(aktif)</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node pway-blocked">
          <div class="pway-icon" style="border-color:var(--red);background:var(--red-d)">âš¡</div>
          <div class="pway-lbl">BRAF<br>V600E</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--amber);background:var(--amber-d)">âš™ï¸</div>
          <div class="pway-lbl">MEK<br>1/2</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--blue);background:var(--blue-d)">ğŸ“¡</div>
          <div class="pway-lbl">ERK<br>1/2</div>
        </div>
        <div class="pway-arrow">â†’</div>
        <div class="pway-node">
          <div class="pway-icon" style="border-color:var(--purple);background:var(--purple-d)">ğŸ”„</div>
          <div class="pway-lbl">HÃ¼cre<br>Proliferasyonu</div>
        </div>
      </div>
      <div style="font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d);margin-top:8px;text-align:center">
        Vemurafenib/Dabrafenib â†’ BRAF'Ä± inhibe eder | Trametinib â†’ MEK'i inhibe eder (kombinasyon tedavisi)
      </div>
    </div>
  </div>

  <div class="drug-grid">
    <div class="drug-card braf">
      <div class="drug-name">Vemurafenib</div>
      <div class="drug-target"><code>BRAF V600E</code> <span>â†’</span> Selektif BRAF inhibitÃ¶rÃ¼</div>
      <div class="drug-indication">â‘  Malin melanom (BRAF V600E+) â‘¡ HCL (refrakter/nÃ¼ks) â‘¢ Langerhans hÃ¼creli histiyositoz</div>
      <div class="drug-note tip">HCL'de refrakter/nÃ¼ks hastalÄ±kta veya aÄŸÄ±r nÃ¶tropeni durumunda kullanÄ±lÄ±r.<sup class="ref">[3,4]</sup></div>
    </div>
    <div class="drug-card braf">
      <div class="drug-name">Dabrafenib + Trametinib</div>
      <div class="drug-target"><code>BRAF + MEK</code> <span>â†’</span> Kombine kinaz inhibitÃ¶rÃ¼</div>
      <div class="drug-indication">Melanom, NSCLC (BRAF V600E+), HCL (refrakter). Kombinasyon direnci azaltÄ±r.</div>
      <div class="drug-note info">Blood 2023: Relaps/refrakter HCL'de Dabrafenib+Trametinib kombinasyonu etkin.<sup class="ref">[4]</sup></div>
    </div>
  </div>

  <div class="tbl-wrap">
    <div class="tbl-cap">Tablo 2. BRAF Ä°nhibitÃ¶rlerinin KullanÄ±m AlanlarÄ±</div>
    <table>
      <thead><tr><th>Ä°laÃ§</th><th>Endikasyon</th><th>Ã–nemli Not</th></tr></thead>
      <tbody>
        <tr>
          <td><strong>Vemurafenib</strong></td>
          <td>Melanom, HCL, Langerhans histiyositoz</td>
          <td><span class="badge red">BRAF V600E zorunlu</span></td>
        </tr>
        <tr>
          <td><strong>Dabrafenib</strong></td>
          <td>Melanom, NSCLC (BRAF+), HCL</td>
          <td><span class="badge amber">Trametinib ile kombinasyon tercih</span></td>
        </tr>
        <tr>
          <td><strong>Dabrafenib+Trametinib</strong></td>
          <td>Melanom, NSCLC, HCL refrakter</td>
          <td><span class="badge green">MEK+BRAF dual blokaj, daha yÃ¼ksek CR</span></td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="sec-title">L-Asparaginaz &amp; Ä°rinotekan â€” Ã–zel Toksisite</div>

  <div class="card-row">
    <div class="card">
      <div class="card-top purple"></div>
      <div class="card-icon">ğŸ§ª</div>
      <div class="card-lbl">L-Asparaginaz</div>
      <div class="card-val">ALL Tedavisi</div>
      <div class="card-desc">Akut lenfoblastik lÃ¶semi tedavisinde kullanÄ±lÄ±r. Ã‡ocuklar iyi tolere eder; eriÅŸkinlerde tolerans daha zayÄ±f. Asparagini yÄ±karak lenfoblast proliferasyonunu baskÄ±lar.<sup class="ref">[6]</sup></div>
    </div>
    <div class="card">
      <div class="card-top red"></div>
      <div class="card-icon">ğŸš¨</div>
      <div class="card-lbl">Ä°rinotekan Toksisitesi</div>
      <div class="card-val">Kolinerjik Sendrom</div>
      <div class="card-desc">Ä°rinotekan infÃ¼zyonu sÄ±rasÄ±nda ani diÄŸare, kolinerjik vazospazm â†’ <strong>Tedavi: Atropin</strong>. 5-FÃœ ile kolorektal kanserde kullanÄ±lÄ±r (FOLFIRI).</div>
    </div>
  </div>

  <div class="info-box red">
    <strong>ğŸš¨ Ä°rinotekan â€” Kolinerjik Sendrom â†’ ATROPÄ°N!</strong> Ä°rinotekan infÃ¼zyonu baÅŸladÄ±ktan 30 dk sonra ani diÄŸare/ishal, terleme, bronkospazm â†’ Kolinerjik vazospazm. <strong>Hemen Atropin</strong> yapÄ±n. Klinik pratikte gÃ¶rÃ¼lmÃ¼ÅŸtÃ¼r; hem TUS hem Yandal Dahiliyesi sÄ±navÄ±nda sorulmuÅŸtur!<sup class="ref">[15]</sup>
  </div>

  <div class="sec-title">Multipl Myelom â€” Proteazom Ä°nhibitÃ¶rleri</div>
  <div class="drug-grid">
    <div class="drug-card other">
      <div class="drug-name">Bortezomib / Karfilzomib / Ä°ksazomib</div>
      <div class="drug-target"><code>Proteazom 26S</code> <span>â†’</span> Proteazom inhibitÃ¶rÃ¼</div>
      <div class="drug-indication">Multipl myelom tedavisinin temel taÅŸlarÄ±. Bortezomib (IV), Karfilzomib (IV), Ä°ksazomib (oral). Birlikte VRd/KRd protokollerinde yer alÄ±r.<sup class="ref">[16]</sup></div>
      <div class="drug-note warn">âš ï¸ Bortezomib: Periferik nÃ¶ropati, herpes zoster reaktivasyonu riski â†’ profilaktik asiklovir.</div>
    </div>
    <div class="drug-card btk">
      <div class="drug-name">Ä°brutinib</div>
      <div class="drug-target"><code>BTK</code> <span>â†’</span> Bruton Tirozin Kinaz inhibitÃ¶rÃ¼</div>
      <div class="drug-indication">KLL / SLL, mantle hÃ¼creli lenfoma, WaldenstrÃ¶m makroglobulinemisi. Oral kullanÄ±m; yÃ¼ksek etkinlik.</div>
      <div class="drug-note tip">KLL'de birinci basamak ve refrakter hastalÄ±kta standart. Hem TUS hem yandal sÄ±navÄ±nda sÄ±klÄ±kla sorulan ajan.<sup class="ref">[5]</sup></div>
    </div>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[3]</span> NCCN Guidelines: Hairy Cell Leukemia. Version 1.2025.</li>
      <li><span class="rn">[4]</span> Falini B, Tiacci E. BRAF V600E mutation in HCL. <em>Blood</em>. 2016;128:1918â€“1927.</li>
      <li><span class="rn">[5]</span> Wierda WG, et al. NCCN Guidelines: CLL/SLL. Version 2.2025.</li>
      <li><span class="rn">[6]</span> Hunger SP, Mullighan CG. ALL in children. <em>N Engl J Med</em>. 2015;373:1541â€“1552.</li>
      <li><span class="rn">[15]</span> Douillard JY, et al. Irinotecan combined with 5-FU for metastatic colorectal cancer. <em>Lancet</em>. 2000;355:1041â€“1047.</li>
      <li><span class="rn">[16]</span> Moreau P, et al. Bortezomib, thalidomide, and dexamethasone in multiple myeloma. <em>N Engl J Med</em>. 2017;376:41â€“51.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s5')">â† Checkpoint</button>
    <button class="btn-next-sec" onclick="goSection('sq')">ğŸ“ Quiz'e BaÅŸla â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• QUIZ â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="sq">
  <p class="page-tag">Bilgi Testi</p>
  <h1 class="page-h1">Hematoloji &amp;<br><em>Onkoloji Quiz</em></h1>
  <div id="quizMain">
    <div class="quiz-prog">
      <span class="quiz-prog-lbl" id="qProgLabel">Soru 1 / 10</span>
      <span class="quiz-score">DoÄŸru: <span class="c" id="qCorrect">0</span> &nbsp;|&nbsp; YanlÄ±ÅŸ: <span class="w" id="qWrong">0</span></span>
    </div>
    <div class="quiz-card">
      <div class="quiz-q" id="qText"></div>
      <div class="quiz-opts" id="qOpts"></div>
      <div class="quiz-fb" id="qFb"></div>
    </div>
    <div class="quiz-actions"><button class="btn-qnext" id="btnNext" disabled>Sonraki â†’</button></div>
  </div>
  <div id="quizResult" style="display:none">
    <div class="result-wrap">
      <div class="ring-wrap">
        <svg width="160" height="160" viewBox="0 0 160 160"><circle class="ring-bg" cx="80" cy="80" r="72"/><circle class="ring-fill" id="ringFill" cx="80" cy="80" r="72"/></svg>
        <div class="ring-inner"><span class="ring-pct" id="rPct">0%</span><span class="ring-sub">BAÅARI</span></div>
      </div>
      <div class="result-title" id="rTitle">â€”</div>
      <div class="result-desc" id="rDesc">â€”</div>
      <div class="result-stats">
        <div class="stat-box"><span class="stat-val" id="rCorrect" style="color:var(--green)">0</span><span class="stat-lbl">DOÄRU</span></div>
        <div class="stat-box"><span class="stat-val" id="rWrong" style="color:var(--red)">0</span><span class="stat-lbl">YANLIÅ</span></div>
        <div class="stat-box"><span class="stat-val" style="color:var(--amber)">10</span><span class="stat-lbl">TOPLAM</span></div>
      </div>
      <div class="result-btns">
        <button class="btn-retry" id="btnRetry">ğŸ”„ Tekrar Et</button>
        <button class="btn-review-all" id="btnReview">ğŸ“š ModÃ¼lÃ¼ Ä°ncele</button>
      </div>
    </div>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• GEÃ‡MÄ°Å â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="sh">
  <p class="page-tag">Puan GeÃ§miÅŸi</p>
  <h1 class="page-h1"><em>Quiz</em> GeÃ§miÅŸi</h1>
  <p class="page-intro">TÃ¼m quiz denemelerinizin kayÄ±tlarÄ± aÅŸaÄŸÄ±da listelenmektedir.</p>
  <div id="histList"></div>
</div>

</main>
</div>

<script>
// â•â•â• QUIZ QUESTIONS â•â•â•
const QUESTIONS=[
  {q:"TÃ¼ylÃ¼ HÃ¼creli LÃ¶semi'de (HCL) tanÄ±mlayÄ±cÄ± genetik mutasyon hangisidir?",opts:["JAK2 V617F","BRAF V600E","BCR-ABL1","IDH1/2"],ans:1,fb:"BRAF V600E, klasik HCL'nin neredeyse %100'Ã¼nde saptanan tanÄ±mlayÄ±cÄ± genetik lezyondur. RAF-MEK-ERK yolaÄŸÄ±nÄ± konstitÃ¼tif aktive eder. HCL-v (varyant formda) bu mutasyon yoktur. [Falini B, NEJM 2024]"},
  {q:"HCL'li bir hastada kemik iliÄŸi aspirasyonu yapÄ±lamÄ±yor. Bu bulgu ne anlama gelir?",opts:["Normal bir biyopsi sonucudur","Yetersiz teknik nedeniyle oluÅŸmuÅŸtur","'Dry tap' â€” kemik iliÄŸi fibrozisine baÄŸlÄ± aspirasyon yapÄ±lamamasÄ±; HCL iÃ§in karakteristik","Myelofibrozis tanÄ±sÄ± konulmalÄ±dÄ±r"],ans:2,fb:"Dry tap (kuru aspirasyon), kemik iliÄŸi fibrozisi nedeniyle aspirasyonun alÄ±namamasÄ±dÄ±r. HCL'de kemik iliÄŸi infiltrasyonu diffÃ¼z ve fibrotik olduÄŸundan aspirasyon genellikle baÅŸarÄ±sÄ±z olur. Bu bulgu HCL iÃ§in Ã§ok karakteristiktir."},
  {q:"HCL'de periferik yaymada monosit sayÄ±sÄ±na iliÅŸkin ne beklenirler?",opts:["Monositoz (artmÄ±ÅŸ monosit)","Normal monosit sayÄ±sÄ±","Monositopeni (sÄ±fÄ±ra yakÄ±n monosit) â€” Ã§ok tipik","Miyelosit artÄ±ÅŸÄ±"],ans:2,fb:"Monositopeni, HCL'nin en tipik periferik yayma bulgularÄ±ndan biridir. Klinisyenler deneyimle periferik yaymada monosit gÃ¶rmediÄŸinde HCL'yi akla getirir. Monosit sayÄ±sÄ± genellikle sÄ±fÄ±ra yakÄ±ndÄ±r."},
  {q:"Kronik Lenfositik LÃ¶semi (KLL) periferik yaymasÄ±nda gÃ¶rÃ¼len karakteristik hÃ¼cre nedir?",opts:["Blast hÃ¼creleri","TÃ¼ylÃ¼ hÃ¼creler","Smudge (smear/ezilmiÅŸ) hÃ¼creleri","Ringed sideroblastlar"],ans:2,fb:"KLL'de kÃ¼Ã§Ã¼k matÃ¼r lenfositler mekanik baskÄ±yla ezilir ve 'smudge' ya da 'smear' hÃ¼cresi adÄ±yla periferik yaymada gÃ¶rÃ¼lÃ¼r. Lenfositoz + smudge hÃ¼cresi = KLL'yi dÃ¼ÅŸÃ¼n."},
  {q:"Setuksimab (Cetuximab) hangi koÅŸulda kolorektal kanserde kullanÄ±labilir?",opts:["Her kolorektal kanserde","YalnÄ±zca KRAS mutasyonu varsa","KRAS wild type (mutasyon yok) kolorektal kanserde","YalnÄ±zca adjuvan tedavide"],ans:2,fb:"Setuksimab bir EGFR monoklonal antikoru; ancak eÄŸer KRAS mutasyonu mevcutsa RAS aÅŸaÄŸÄ± sinyal devam ettiÄŸinden setuksimab etkisizdir. Bu nedenle setuksimab verilmeden Ã¶nce KRAS wild type teyit edilmelidir. [Van Cutsem E, NEJM 2009]"},
  {q:"Ä°pilimumab (anti-CTLA-4) ile tedavi edilen bir melanom hastasÄ±nda yorgunluk, baÅŸ aÄŸrÄ±sÄ± ve hiponatremi geliÅŸti. En olasÄ± neden nedir?",opts:["Ä°laÃ§ toksisitesi nedeniyle karaciÄŸer yetmezliÄŸi","Ä°mmÃ¼n iliÅŸkili otoimmÃ¼n hipofizit","Beyin metastazÄ±","Ä°laÃ§ aÅŸÄ±rÄ± duyarlÄ±lÄ±k reaksiyonu"],ans:1,fb:"Ä°pilimumab'Ä±n en karakteristik otoimmÃ¼n yan etkisi hipofizittir. Ä°nsidansÄ± monoterapide %3-6, kombinasyonda %8-14. Yorgunluk + baÅŸ aÄŸrÄ±sÄ± + hiponatremi + TSH/kortizol bozukluÄŸu â†’ otoimmÃ¼n hipofizit dÃ¼ÅŸÃ¼n. [Zhao C, Front Oncol 2022]"},
  {q:"HCL birinci basamak tedavisinde hangi ajan tercih edilir?",opts:["Rituksimab monoterapisi","Ä°brutinib","Kladribin (Â± rituksimab)","Vemurafenib"],ans:2,fb:"Kladribin (2-CdA), HCL'de birinci basamak standart tedavidir. Tek kÃ¼r ile %80-95 tam remisyon saÄŸlar. Rituksimab ile kombinasyon minimal rezidÃ¼el hastalÄ±k oranÄ±nÄ± azaltÄ±r. Vemurafenib ve dabrafenib nÃ¼ks/refrakter hastalÄ±kta veya yoÄŸun immÃ¼nsÃ¼presyon riski olan hastalarda kullanÄ±lÄ±r. [NCCN 2025]"},
  {q:"Ä°rinotekan infÃ¼zyonu sÄ±rasÄ±nda ani diare ve kolinerjik belirtiler geliÅŸti. Tedavisi nedir?",opts:["Adrenalin","Atropin","Kortikosteroid","Ä°laÃ§ kesilir, baÅŸka tedavi gerekmez"],ans:1,fb:"Ä°rinotekan aktif metaboliti SN-38 ile kolin esteraz inhibisyonu yoluyla kolinerjik sendroma neden olabilir. Ani diare, terleme, kolinerjik vazospazm gÃ¶rÃ¼lÃ¼r. Tedavisi atropindir. Hem TUS hem yandal dahiliye sÄ±navÄ±nda sorulmuÅŸ klinik bir durumdur."},
  {q:"Hangi checkpoint inhibitÃ¶rÃ¼ Hodgkin Lenfoma tedavisinde Ã¶zellikle kullanÄ±lÄ±r?",opts:["Ä°pilimumab (anti-CTLA-4)","Nivolumab veya Pembrolizumab (anti-PD-1)","Atezolizumab (anti-PD-L1)","Durvalumab (anti-PD-L1)"],ans:1,fb:"Nivolumab ve Pembrolizumab (anti-PD-1), Hodgkin Lenfoma'da FDA onaylÄ± checkpoint inhibitÃ¶rleridir. Hodgkin lenfomada Reed-Sternberg hÃ¼creleri Ã¼zerinde PD-L1 ekspresyonu yÃ¼ksektir. Brentuximab vedotin (anti-CD30) de Hodgkin'de kullanÄ±lmaktadÄ±r."},
  {q:"EGFR tirozin kinaz inhibitÃ¶rleri (erlotinib, gefitinib) hangi akciÄŸer kanseri grubunda kullanÄ±lÄ±r?",opts:["Her NSCLC hastasÄ±nda","EGFR mutasyonu pozitif NSCLC (Ã¶zellikle adenokarsinom)","KÃ¼Ã§Ã¼k hÃ¼creli akciÄŸer kanserinde","KRAS mutasyonu olan hastalarda"],ans:1,fb:"Erlotinib, gefitinib ve afatinib EGFR mutasyonu (exon 19 delesyonu veya exon 21 L858R) pozitif kÃ¼Ã§Ã¼k hÃ¼cre dÄ±ÅŸÄ± akciÄŸer kanserinde (NSCLC) kullanÄ±lÄ±r. EGFR mutasyonu genellikle adenokarsinomda, sigara iÃ§meyenlerde ve Asya populasyonunda daha sÄ±k. Son Yandal Dahiliye sÄ±navÄ±nda da sorulmuÅŸtur."}
];

let cUser='',qIdx=0,qCorr=0,qWrong=0,qAns=false;

async function sGet(k){try{const r=await window.storage.get(k);return r?JSON.parse(r.value):null}catch{return null}}
async function sSet(k,v){try{await window.storage.set(k,JSON.stringify(v))}catch{}}

// LOGIN
document.getElementById('loginBtn').addEventListener('click',doLogin);
document.getElementById('loginName').addEventListener('keydown',e=>{if(e.key==='Enter')doLogin()});
function _applyLoginHema(nm){
  cUser=nm;
  localStorage.setItem('sweetyhard_lms_user',nm);
  const ls=document.getElementById('loginScreen');
  ls.style.opacity='0';
  setTimeout(()=>{ls.style.display='none';document.getElementById('app').style.display='block'},480);
  document.getElementById('topbarUser').textContent=nm;
  initQuiz();renderHistory();
}
function doLogin(){
  const nm=document.getElementById('loginName').value.trim();
  if(!nm){document.getElementById('loginName').focus();return}
  _applyLoginHema(nm);
}
window.autoLogin=function(u){_applyLoginHema(u);};
// Sayfa aÃ§Ä±lÄ±ÅŸÄ±nda kayÄ±tlÄ± kullanÄ±cÄ±yÄ± kontrol et
(function(){const s=localStorage.getItem('sweetyhard_lms_user');if(s)setTimeout(()=>_applyLoginHema(s),100);})();
document.getElementById('logoutBtn').addEventListener('click',()=>{
  localStorage.removeItem('sweetyhard_lms_user');
  document.getElementById('app').style.display='none';
  const ls=document.getElementById('loginScreen');
  ls.style.display='flex';ls.style.opacity='1';
  document.getElementById('loginName').value='';
  const nav=document.getElementById('lms-nav');if(nav)nav.remove();
});

// SECTION NAV
function goSection(id){
  document.querySelectorAll('.sec-tab').forEach(b=>b.classList.remove('active'));
  const tab=document.querySelector(`[data-sec="${id}"]`);
  if(tab){tab.classList.add('active');document.getElementById('topProgress').style.width=(tab.dataset.prog||'0')+'%'}
  document.querySelectorAll('.sec-page').forEach(p=>p.classList.remove('active'));
  const page=document.getElementById(id);
  if(page)page.classList.add('active');
  if(id==='sq')initQuiz();
  if(id==='sh')renderHistory();
  window.scrollTo({top:0,behavior:'smooth'});
}
document.querySelectorAll('.sec-tab').forEach(b=>b.addEventListener('click',()=>goSection(b.dataset.sec)));

// ACCORDION
document.querySelectorAll('.accord-head').forEach(h=>h.addEventListener('click',()=>h.parentElement.classList.toggle('open')));

// TTS
let ttsOn=false;
document.getElementById('ttsBtn').addEventListener('click',()=>{
  if(!('speechSynthesis' in window))return;
  if(ttsOn){window.speechSynthesis.cancel();ttsOn=false;document.getElementById('ttsBtn').textContent='ğŸ”Š Sesli Oku';document.getElementById('ttsBtn').classList.remove('speaking');return}
  const pg=document.querySelector('.sec-page.active');if(!pg)return;
  let txt='';
  pg.querySelectorAll('.page-intro,.info-box,.card-desc,.accord-body,td,.algo-txt,.drug-indication,.drug-note').forEach(el=>{txt+=el.innerText+' '});
  txt=txt.replace(/\s+/g,' ').trim();if(!txt)return;
  const u=new SpeechSynthesisUtterance(txt);u.lang='tr-TR';u.rate=0.95;
  u.onend=()=>{ttsOn=false;document.getElementById('ttsBtn').textContent='ğŸ”Š Sesli Oku';document.getElementById('ttsBtn').classList.remove('speaking')};
  ttsOn=true;document.getElementById('ttsBtn').textContent='â¹ Durdur';document.getElementById('ttsBtn').classList.add('speaking');
  window.speechSynthesis.speak(u);
});

// QUIZ
function initQuiz(){
  qIdx=0;qCorr=0;qWrong=0;qAns=false;
  document.getElementById('qCorrect').textContent='0';
  document.getElementById('qWrong').textContent='0';
  document.getElementById('quizMain').style.display='block';
  document.getElementById('quizResult').style.display='none';
  document.getElementById('ringFill').style.strokeDashoffset='452';
  renderQ();
}
function renderQ(){
  qAns=false;
  const q=QUESTIONS[qIdx];
  document.getElementById('qProgLabel').textContent=`Soru ${qIdx+1} / ${QUESTIONS.length}`;
  document.getElementById('qText').textContent=q.q;
  document.getElementById('qFb').className='quiz-fb';
  document.getElementById('qFb').textContent='';
  document.getElementById('btnNext').disabled=true;
  document.getElementById('btnNext').textContent=qIdx===QUESTIONS.length-1?'SonuÃ§larÄ± GÃ¶r â†’':'Sonraki â†’';
  const opts=document.getElementById('qOpts');opts.innerHTML='';
  ['A','B','C','D'].forEach((k,i)=>{
    const btn=document.createElement('button');
    btn.className='quiz-opt';
    btn.innerHTML=`<span class="opt-key">${k}</span><span>${q.opts[i]}</span>`;
    btn.addEventListener('click',()=>selectOpt(i));
    opts.appendChild(btn);
  });
}
function selectOpt(idx){
  if(qAns)return;qAns=true;
  const q=QUESTIONS[qIdx];
  const btns=document.querySelectorAll('.quiz-opt');
  btns.forEach(b=>b.setAttribute('disabled',''));
  const fb=document.getElementById('qFb');
  if(idx===q.ans){btns[idx].classList.add('correct');qCorr++;document.getElementById('qCorrect').textContent=qCorr;fb.textContent='âœ… DoÄŸru! '+q.fb;fb.className='quiz-fb show ok';}
  else{btns[idx].classList.add('wrong');btns[q.ans].classList.add('correct');qWrong++;document.getElementById('qWrong').textContent=qWrong;fb.textContent='âŒ YanlÄ±ÅŸ. '+q.fb;fb.className='quiz-fb show ko';}
  document.getElementById('btnNext').disabled=false;
}
document.getElementById('btnNext').addEventListener('click',()=>{qIdx++;if(qIdx>=QUESTIONS.length){showResult();return}renderQ();});
async function showResult(){
  document.getElementById('quizMain').style.display='none';
  document.getElementById('quizResult').style.display='block';
  const pct=Math.round((qCorr/QUESTIONS.length)*100);
  document.getElementById('rPct').textContent=pct+'%';
  document.getElementById('rCorrect').textContent=qCorr;
  document.getElementById('rWrong').textContent=qWrong;
  let t,d;
  if(pct>=90){t='ğŸ† MÃ¼kemmel!';d='Hematoloji ve hedefe yÃ¶nelik tedavilere hakimiyetiniz Ã§ok iyi. Klinik pratikte gÃ¼venle uygulayabilirsiniz.'}
  else if(pct>=70){t='ğŸ“ˆ Ä°yi Ã‡alÄ±ÅŸma!';d='Temel kavramlarÄ± kavramÄ±ÅŸsÄ±nÄ±z. BRAF inhibitÃ¶rleri, checkpoint ilaÃ§larÄ± ve CD hedefleri konularÄ±nÄ± gÃ¶zden geÃ§irin.'}
  else if(pct>=50){t='ğŸ“š Tekrar Ã–nerilir';d='Ã–zellikle HCL tanÄ±sÄ±, KLL periferik yaymasÄ± ve akÄ±llÄ± ilaÃ§ endikasyonlarÄ±nÄ± yeniden Ã§alÄ±ÅŸÄ±n.'}
  else{t='ğŸ”„ ModÃ¼lÃ¼ BaÅŸtan Ä°nceleyin';d='Her bÃ¶lÃ¼mÃ¼ referanslarÄ±yla birlikte okuyun, ilaÃ§ kartlarÄ±na odaklanÄ±n, ardÄ±ndan tekrar deneyin.'}
  document.getElementById('rTitle').textContent=t;document.getElementById('rDesc').textContent=d;
  const circumference=452;
  setTimeout(()=>{document.getElementById('ringFill').style.strokeDashoffset=circumference-(circumference*pct/100)},300);
  const k=`hemaonko_${cUser}`;
  const ex=await sGet(k)||[];
  ex.unshift({pct,correct:qCorr,wrong:qWrong,date:new Date().toLocaleString('tr-TR')});
  if(ex.length>20)ex.pop();
  await sSet(k,ex);
}
document.getElementById('btnRetry').addEventListener('click',initQuiz);
document.getElementById('btnReview').addEventListener('click',()=>goSection('s1'));

// HISTORY
async function renderHistory(){
  const el=document.getElementById('histList');
  if(!cUser){el.innerHTML='<div class="empty-hist">GiriÅŸ yapÄ±nÄ±z.</div>';return}
  const scores=await sGet(`hemaonko_${cUser}`);
  if(!scores||!scores.length){el.innerHTML='<div class="empty-hist">HenÃ¼z quiz tamamlanmamÄ±ÅŸ.</div>';return}
  const medals=['ğŸ¥‡','ğŸ¥ˆ','ğŸ¥‰'];
  el.innerHTML='<div class="hist-list">'+scores.map((s,i)=>`
    <div class="hist-item">
      <span class="hist-rank">#${i+1}</span>
      <span class="hist-score" style="color:${s.pct>=70?'var(--green)':s.pct>=50?'var(--amber)':'var(--red)'}">${s.pct}%</span>
      <div class="hist-meta"><div class="hist-date">${s.date}</div><div class="hist-correct">DoÄŸru: ${s.correct} / YanlÄ±ÅŸ: ${s.wrong}</div></div>
      <span style="font-size:22px">${medals[i]||'ğŸ“‹'}</span>
    </div>`).join('')+'</div>';
}
</script>
<script src="nav.js"></script>
</body>
</html>
